Molecular studies on hepatitis B virus induced hepatocellular carcinoma by est sequencing and suppression subtractive hybridization. by Yu, Chi Hung. & Chinese University of Hong Kong Graduate School. Division of Biochemistry.
MOLECULAR STUDIES ON HEPATITIS B 
VIRUS INDUCED HEPATOCELLULAR 





YU CHI HUNG 
> 
A Thesis Submitted in Partial Fulfillment ofthe Requirements 
for the Degree ofMaster ofPhilosophy in Biochemistry 
JULY 2000 
DEPARTMENT OF BIOCHEMISTRY 
• T H E CHINESE UNIVERSITY OF HONG KONG 
The Chinese University ofHong Kong holds the copyright ofthis thesis. 
Any person(s) intending to use a part or whole of the materials in the 
thesis in a proposed publication must seek copyright release from the 
Dean of the Graduate School. 
, / ^ ^ v 
/ y j i i £ £ a 3 A 






I would like to thank my supervisor Prof. Stephen K.W. Tsui for his guidance and 
spiritual support throughout my study. Without his advice and support, the writing of 
this thesis would be impossible. 
I would also like to express my heartful thanks to Prof. Mary M.Y. Waye, who has 
showed us a good model to be a good scientist. I also thank all of my colleagues, 
especially Mr Stephen S.C. Chlm and Mr Thomas C.C. Au for their technical 
supports in carrying out some experiments. Last but not least, may I thank God for 
giving me the chance, the wisdom, the strength throughout my study and also giving 
me the above persons in my life. ‘ 
This project is partly supported by grants from the Industry Department, HKSAR 
Government, AF/97/98 and AF/9/97. 
«» 
i 
Table of Contents 
Acknowledgement [ 
Table of Contents i [ 
Abbreviations [ y 
Abstract v 
論文摘要 v i 
Chapter 1 Introduction . 1 
1.1 General introduction 
1.2 HBV and its potential oncogenic properties 
1.3 Aim of the present study 
1.4 Expressed sequence tag (EST) analysis: an approach to reveal 
gene expression pattern in a specific tissue 
1.5 cDNA subtraction 
Chapter 2 Materials and Methods 17 � 
2.1 Plating out the adult human normal liver cDNA library 
2.2 PCR amplification of cloned human normal liver cDNA inserts 
2.3 Cycle sequencing of cloned human normal liver cDNA inserts 
2.4 mRNA preparation from the HCC tissue and its stoounding 
normal counterpart 
2.5 PCR-Select cDNA subtraction 
2.6 Construction of HCC subtracted cDNA library by T/A cloning 
method 
2.7 PCR amplification of cloned subtracted cDNA 
2.8 Cycle sequencing of cloned subtracted cDNA 
2.9 Sequence analysis 
2.10 Differential hybridization of HCC subtracted clones 
Chapter 3 Results 46 
3.1 The sequencing results of adult human normal liver cDNA 
clones 
3.2 Categorization of ESTs sequenced from the adult normal liver 
3.3 Adaptor ligation efficiency analysis 
3.4 Primary and secondary PCR Amplification 
3 • 5 PCR analysis of subtraction efficiency 
3.6 The sequencing results of subtracted HCC cDNA clones 
3.7 Categorization of ESTs sequenced from the subtracted HCC 
cDNA library 
3.8 Differential hybridization of subtracted cDNA clones 
ii 
Table of Contents (continued) 
Chapter 4 Discussions % 
4.1 Characterization of the ESTs generated from human normal 
liver cDNA library 
4.2 EST analysis on subtracted HCC cDNA clones 
4.3 Candidate genes differentially expressed in HCC 
Appendix A The coordinates of dot blots (in numerical order according to 
clone numbers) 
Appendix B The coordinates of dot blots (in alphabetical order according to 
putative identity) 







BSA bovine serum albumin 
EST expressed sequence tag 
HBV hepatitis B virus 
HBx hepatitis B x antigen 
HCC hepatocellular carcinoma 
PCR polymerase chain reaction 







Hepatocellular carcinoma (HCC) is among the most common cancers in the world 
and one of rare human cancers showing close relationship with viral infection. 
Hepatitis B virus (HBV) is the major etiological factor of HCC development. In 
Hong Kong, liver cancer is the second commonest cause ofcancer death. Up to now, 
the full picture of HBV-induced HCC is still unclear. In order to investigate the 
change in gene expression in HCC of local Chinese, our laboratory made use of 
random sequencing of three human liver cDNA libraries to identify and tag genes 
expressed in normal liver tissues and HBV-induced HCC tissues. In this project, a 
catalogue of 500 expressed sequence tags (EST) sequenced from a normal liver 
� 
cDNA library was presented. This group of data represents the expression profile of 
normal liver and was used as a control for comparison to that generated from the 
other HCC cDNA library and its matched normal cDNA library. These results may 
provide insight into the change of expression profile and differential gene expression 
% 
during HCC development. In addition, suppression subtractive hybridization (SSH) 
was also adopted to identify genes that are up-regulated during hepatocarcinogenesis. 
Up to date, at least 70 genes are suggested to be candidate genes overexpressed in 
HCC upon differential screening. Their significance and involvement in cancer 
























1.1 General introduction 
This thesis will be divided into four chapters. Chapter one will focus on the general 
1» 
introduction and various basic knowledge of the pathogenesis of hepatitis B vims 
r 
(HBV) -induced hepatocellular carcinoma (HCC) based on present studies and the 
current situation in Hong Kong. Then, the application of expressed sequence tag 
(EST) approach in studying gene expression in human normal liver and its 
、 
importance in revealing the alteration of gene expression in HCC will be described. 
Furthermore, the molecular basis of constructing subtracted HCC library by means 
of suppression subtractive hybridization (SSH) and its significance in acting as a 
complementation approach to identify differential gene expression and novel tumor 
markers will also be discussed in the final section of this chapter. 
Chapter two will describe the basic strategies and methods we employed in carrying 
out large scale EST sequencing, construction of subtracted HCC cDNA library by 
means of SSH, and differential screening on SSH-generated cDNAs. Chapter three 
will present the sequencing result of the cDNA clones obtained from human normal 
liver and subtracted HCC libraries, the catalogues of gene expressed as well as the 
ESTs distribution profiles in these two cDNA libraries. The results of molecular 
analyses on subtracted HCC cDNA library will also be described. 
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The last chapter will discuss the insight we gained during the human liver EST 
sequencing. Furthermore, the importance and significance of genes identified as 
strong candidates of differential expression from the subtracted HCC cDNA library 






1.2 HBV and its potential oncogenic properties 
1.2.1 The current situation of hepatitis B infection and HBV 
induced HCC in Hong Kong {Public Health Report, 1998) 
World Health Organization (WHO) has estimated that hepatitis B infection solely 
accounted for 1.1 million deaths and was the fifth major cause ofdeath in 1995. This 
sero-transmitted disease is highly prevalent (i.e., over 8% of total populations are 
carriers) in mainland China, Southeast Asia and sub-Saharan Africa; and it shows 
seroepidemiological association with HCC (Figure 1.1). Focusing on the situation in 
Hong Kong, it was estimated that about 10% ofthe whole population are hepatitis B 
carriers with a male predominance (males: 11.0%, females 6.1 %). � 
The long term consequences of chronic viral hepatitis infection, which include liver 
cancer, chronic liver disease and cirrhosis, led to 5.5% ofall deaths in Hong Kong in 
1995. Among all the different types of viral hepatitis, hepatitis B infection is most 
noticeable in leading to chronic liver disease in Hong Kong. It was found that 25% 
of hepatitis B chronic carriers might die because of its long term effects. Liver 
cancer is the second commonest cause of cancer deaths and there is a male 
predominance with sex ratio about 3:1. Local studies showed that approximately 
80% ofpatients with HCC, the most common type of liver cancer, were found to be 
hepatitis B carriers. Such findings suggest that hepatitis B infection, being the major 
risk factor for the development ofHCC, plays an important role in the pathogenesis 
ofHCC. Other prospective study also estimated there is a 100-fold increased risk of 
developing HCC for chronic HBV carriers as compared with the non-infected 
population (Beasley et aL, 1981). 
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1.2.2 The genomic organization of HBV 
Before we concentrate on the possible oncogenic mechanism induced by HBV, we 
must have some basic knowledge of HBV. HBV genome consists of an 
approximately 3.2kb circular molecule that is partially double stranded, reflecting the 
fact that DNA molecules are packaged into virions before the completion of viral 
DNA replication. Four primary translation open reading frames (ORFs) have been 
identified in the complete or long (-) virion DNA strand. They encode the viral 
proteins: (1) the viral envelope, which exhibits hepatitis B surface antigen (HBsAg) 
specificity; (2) the viral core, which exhibits hepatitis B core antigen (HBcAg) and 
its truncated form contains hepatitis B e antigen specificity (HBeAg) specificity; (3) � 
the DNA polymerase, which also possesses reverse transcriptase activity and 
RNaseH activity and acts as protein primer during viral DNA replication; (4) the 
smallest X protein (HBx), which has the capacity to transactivate both homologous 
and heterologous regulatory elements. The transcription of these four ORFs is 
regulated by four promoter elements (preSl, preS2, Cp, and Xp) and two enhancer 
elements (ENH1 and ENH2) (Figure 2). 
1.2.3 Possible oncogenic mechanisms for hepato-
carcinogenesis induced by HBV 
Integrated HBV sequences have been observed in about 80% ofhuman HCCs and in 
established hepatoma cell lines (Brechot et cd.，1980; Chakraborty et aL, 1980; 
Edman et al., 1980; Brechot et al； 1981; Shafritz et al, 1981). Though integration of 
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viral DNA into the host genome might cause direct activation of proto-oncogene or 
secondary chromosomal alterations, it has been only described in rare cases (Dejean 
et al., 1986; Graef et aI., 1994). Other studies on viral DNA integrations in many 
human HCCs have found that integration can take place at multiple sites on various 
chromosomes. The inserted sequences are fragmented and rearranged, reflecting the 
fact that viral DNA integration does not occur through a unique mechanism. 
However, simple repetitive elements have been suggested as hotspots for viral DNA 
insertion in the human genome O^agaya et al., 1983; Shaul et cd., 1986; Berger and 
Shaul, 1987). Nevertheless, it is generally considered that the viral DNA integration 
does not have any direct mutagenic effect on cell growth control genes. But it may 
act as a random mutagen that enhances chromosomal instability since large inverted 
duplications, deletions, amplifications, or chromosomal translocations have been � 
reported to be associated with HBV insertions (Hatada et al., 1988; Hino et al., 1986; 
Koch et aL, 1984; Mizusawa et al., 1985; Rogler et al., 1985; Tokino et al, 1987; 
Yaginuma et aL, 1987). Besides this, a portion of viral junctions were found to be 
localized in the carboxy-terminal part of the viral gene, predicting a fusion of the X 
ORF with flanking cellular sequences in a way that might preserve the functional 
capacity o f the X transactivator. Evidence for transcriptional activity at integrated X 
sequences has been provided in HCC tissues and chronically infected tissues. The 
contribution of downstream cellular sequences to activated expression and/or to 
enhanced trans-activating capacities of the integrated HBV sequences has been 
suggested (Wollersheim et al, 1988). But it is considered such mechanism only 
contribute in a small percentage oftumors. 
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Transcriptional transactivation by viral proteins was another proposed potential 
oncogenic mechanism induced by HBV. As mentioned above, the X gene can be 
expressed by integrated HBV-DNA or by episomal or replicating forms of HBV-
DNA. HBx expression in partially transformed cells such as NIH3T3 or mouse 
hepatocyte cell line expressing SV40 T antigen resulted in altered cell growth, 
rendered the cells able to grow into colonies in soft agar and forming tumors in nude 
mice (Koike et al., 1989; Robinson et al., 1990; Hohne et al, 1990). In a transgenic 
mice model, the transgenic mice carrying HBx gene under the control of HBV 
II 
enhancer and HBx promotor altered hepatocyte morphology, followed by adenomas 
and finally HCC. HBx expression in certain cell lines has been reported to activate 
transcription of certain cellular protooncogenes like c-myc and c-jun (Koike et al., 
1989; Twu et al., 1993). Recent studies revealed that transactivation by HBx occurs � 
via the signal transduction pathways. First, HBx was found to stimulate API and 
NFKB-regulated gene expression through protein kinase C (PKC) signalling pathway 
by increasing endogenous PKC activator sn-1,2-diacylglycerol (Kekule et al., 1990, 
1992). Another study suggested that activation ofNFKB may be mediated by the 
action of reactive oxidative intermediates (Meyer et al., 1992). Besides, HBx can 
interfere with the signalling cascade comprising ras, raf-l, mitogen-activated protein 
kinase kinase (MAPKK) and mitogen-activated protein kinase (MAPK) to stimulate 
AP-l-mediated transcription (Benn & Schneider, 1994). HBx was found to induce an 
increase in GTP binding of ms, leading to the activation of this signalling pathway. 
In some cell lines, like HepG2, HeLa and CV1, HBx also led to a ras-raf dependent 
increase in the DNA binding activity of API. In addition, HBx is able to complex 
with and alter the binding specificities of the cyclic AMP-induced transcription 
factors CREB and ATF-2 (Maguire et cd., 1991; Williams & Andrisani，1995). Other 
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in vitro experiments shown that HBx has the potential to interact with several 
components of the basal transcription complex, such as the TATA-binding protein 
(TBP), RNA polymerase subunit 5B, and the ERCC2 and ERCC3 DNA helicase 
subunits ofTFIIH (Qadri et al., 1995，1996; Cheong et aL, 1995). 
On the other hand, Feitelson and his co-workers reported that HBx and p53 were co-
immunoprecipitated from lysates of HBV-induced HCC cells using antibodies 
against either one (Feitelson et aL, 1993). Being a tumor suppressor protein, p53 
normally binds to specific sequences in the regulatory elements of genes involved in 
cell cycle in order to facilitate its cell cycle control function. Though there is an 
interaction between HBx and p53, the DNA binding site of p53 is not altered (Wang 
et aL, 1995). And it is suggested that HBx may contain a repression domain which � 
may down-regulate transcription by direct interaction with p53-bound DNA (Truant 
et aL, 1995). In the HBx transgenic mice model that develops to HCC, p53 was 
shown to be bound to and co-localized with HBx in the cytoplasm of the tumor cells 
(Ueda et aL, 1995). Its cytoplasmic sequesteration implied to its functional 
inactivation and it was proposed to be significantly related to HBV-mediated 
transformation. Despite the fact that various mechanisms have been proposed upon 
interactions of HBx with p53, their significance in HBV-mediated 
hepatocarcinogenesis remains to be confirmed and clarified in human HCC. Other 
than interacting with HBx, allele loss of the short arm of chromosome 17, which 
include the p53 gene, has been observed in 30% to 60% of human HCCs. Mutant 
forms were also found in most established HCC cell lines. Losing normal p53 
function in hepatocytes would surely lead to deregulation of the cell cycle, but the 
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relationship between genetic alterations of p53 and HBV infection remains to be 
elucidated. 
Undoubtedly, there is a strong connection between chronic HBV infection and HCC 
development. However, none of the viral proteins was found to act as a strong, 
dominant oncogene. Though viral X transactivator might participate in 
hepatocarcinogenesis in a native or modified state and recent data support a 
predominant role that tumor suppressor gene plays p53 in HCC, it is considered that 
I* 
oncogenic mechanisms mediated by HBV is somehow not so simplistic. Various and 
probably cooperative mechanisms may be involved in hepatocarcinogenesis rather 
than a single action of a viral protein or the consequence of viral DNA integration. 
Due to the complexity of the whole picture, the underlying principle of HBV- � 
induced hepatocarcinogenesis is still unclear and demand further investigations. 
1.2.4 Current screening test and therapies for HCC ("Update 
on Hepatocellular Carcinoma" from HepNet) 
Alpha-fetoprotein (AFP) and abdominal ultrasound screening test have been widely 
adopted in clinical settings to detect asymptomatic or subclinical HCC in high risk 
group. AFP is an oncofetal protein, produced by the normal human fetus up to the 
time of birth. In HCC, AFP is once again produced by the tumor cells. Though these 
two tests are widely used to screen for HCC, neither was adequately sensitive. Serum 
AFP concentration under 20ng/ml is usually not diagnostic. In a prospective study of 
1069 HBV chronic carriers, 64.3% and 71.4% of HCC patients show positive result 
in AFP and abdominal ultrasound test respectively. While both tests had a high 
negative predictive value (i.e., negative results in both tests are almost correct in 
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suggesting the absence of HCC), the positive predictive value was low. Only 9% 
patient with an elevated AFP turned out having HCC. It is because elevated AFP is 
also seen in patients with chronic liver disease, resulting in false-positive results for 
liver cancer screening. Positive ultrasound also only indicated cancer injust 18.5%. 
Indeed, very few therapies are applicable to treat HCC. Conventional cancer 
therapies such as chemotherapy and radiotherapy are not effective in treating HCC, 
because of lack of effect and toxicity. Surgery (hepatic resection) offers the best 
chance of cure, although the five-year survival rate is merely 30-40% in good 
candidates. And this method is only applicable to patients without cirrhosis and with 
tumor size less than 5 cm in diameter. Liver transplantation is another choice that 
gives a good five-year survival rate (60% - 80%), but it is well known that it is � 
difficult to find a suitable graft organ. For patients with small size tumors and 
cirrhosis, percutaneous ethanol injection may be an alternative option. Apart from 
these treatment currently used, some other techniques, such as microwave ablation, 
proton irradiation, and laser hyperthermia, are under investigation for effective 




Figure 1.1 Geographic distribution of chronic HBV infection (above) and 
World annual incidence of HCC (bottom). The epidemiological pattem of chronic 
HBV infection is very consistent with that of HCC suggesting that chronic HBV 
infection is the major risk factor for the development of HCC. (Adapted from 
Centers and Disease Control and Prevention, 1996; and World Health Report，1996) 
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Figure 1.2 Genome organization of HBV. The inner cycle shows a restriction 
map of HBV subtype ayw genome (Galibert et aL, 1979). The partially double 
stranded genome is represented as a thick line and the dashed line in the short (+) 
DNA represents the region within which the 3' end of the + strand may occur in 
different molecules. Four open reading frames encoding seven peptides are indicated 
by large arrows. DR1 and DR2 are two directly repeated sequences located at the 
h 
extremities of the viral DNA strands. (Adapted from Buendia et aL, 1998) 
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1.3 Aim of the present study 
To reveal the genes expressed in normal liver and HCC, EST approach and SSH 
strategy have been employed in order to study genes differentially expressed during 
hepatocarcinogenesis and establishing a database resource for searching tumor 
markers of HCC. In this project, extensive sequencing and functional categorization 
of cDNA clones derived from human normal cDNA library have been carried out as 
control group data for further analysis (i.e., compared with the data derived from 
HCC cDNA library). Also, a subtracted HCC cDNA library has been constructed as 
a complementation to EST project to identify differentially expressed transcripts in 





1.4 Expressed sequence tag (EST) analysis: an approach 
to reveal gene expression pattern in a specific tissue 
EST refers to a segment of a sequence from a cDNA clone that corresponds to a 
mRNA transcript. This segment can provide sufficient information to enable putative 
identification of the gene from which the cDNA was derived. Being one of the 
important progress in the human genome project, nearly all early EST studies have 
focused on gene discovery, mapping of the human genome, and searching for the 
gene coding regions. Since its introduction in 1991, the EST approach has been used 
to characterize expressed genes in a variety of human tissues in different 
developmental stages (Adams et cd., 1991, 1992 & 1993; Okubo et al., 1992; Khan 
et aL, 1992; Gieser and Swaroop, 1992; Park et al., 1993; Takeda et aL, 1993; Collet � 
and Joseph, 1994; Liew et cd., 1994; Hwang et aL, 1995). For example, Adams and 
his co-workers identified human homologs of Drosophila genes Notch and Enhancer 
of Split by sequence similarities searches using ESTs (Adams et aL, 1991). Their 
research group has also sequenced more than 174,000 human ESTs from 300 cDNA 
libraries constructed from 37 distinct tissues (Adams et aL, 1995). Huge number of 
ESTs sequences generated by different research groups have been submitted to a 
special database of GenBank called dbEST for storage (Boguski et al., 1993). Up to 
now (July 2000), over 5,000,000 entries are present in dbEST database. Over 40% of 
entries are human ESTs while the others come from 251 different organisms. The 
dbEST data are readily accessed through Internet 
(http://www.ncbi.nlm.nih.gov/dbEST/). Different ESTs on the databse can be 
aligned in order to search for a full-length sequence of gene from this resource. 
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EST approach has also been proven to be a rapid and efficient means of providing 
both quantitative and qualitative information regarding gene expression in certain 
tissue or cell types (Okubu et aL, 1992). Partial cDNA sequencing of randomly 
selected clones from oligo(dT)-primed cDNA library can provide quantitative 
information about the expression level of certain gene based on measurement of EST 
frequency. Furthermore, functional categorization of ESTs with known gene matches 
can be used to point out general differences in gene expression between two tissues. 
In addition to observation of global expression profiles, EST data can also be used to 
evaluate single gene expression in various tissues with different developmental or 
pathological states. Genes overexpressed in cardiac hypertrophy have been identified 
with this approach in a large scale human heart EST project (Hwang et al, 1997 & 
2000). � 
Though there are some minor drawbacks regarding the research on EST project, 
一 
including high redundancy of abundantly expressed or overexpressed genes and 
difficulty in tagging rarely expressed transcripts, EST approach has proven to be an 
effective and powerful tool for differential gene expression study and contributes 




1.5 cDNA subtraction 
In higher eukaryotes, different biological events such as cell proliferation, 
differentiation and tissue development are thought to be mediated by precise and 
strictly controlled programs of differential gene expression. In order to reveal the 
underlying molecular principles of these biological events, the relevant subsets of 
differentially expressed genes must be identified and studied in detail. Previous 
reports have shown that subtractive hybridization is a powerful approach which 
enables the comparison of two populations of mRNA, identification and isolation of 
cDNAs of differentially expressed genes. Different kinds of cDNA subtraction 
methods have been developed by many researchers. General speaking, the basic 
principle involved the conversion from two mRNA populations into cDNA and � 
hybridization of the two cDNA populations. The cDNA that one wish to find 
differentially expressed transcripts is known as the "tester", and the reference cDNA 
is known as the "driver". The tester cDNA was hybridized to excess driver cDNA 
and then accompanied with separation of the unhybridized fraction from hybridized 
common sequences by hydroxylapatite chromatography (Hedrick et cd., 1984), 
avidin-biotin binding (Sargent et al., 1983; Duguid and Dinauer, 1990), or oligo-dT 
latex beads (Hara et al., 1991). Though these traditional methods were successful in 
identifying numerous target genes, the experimental process is tedious and labor 
intensive. Also, they are usually inefficient in identifying those differentially 




Diatchenko and his co-workers developed a new PCR-based cDNA subtraction 
method, termed suppression subtractive hybridization (SSH), and demonstrated its 
effectiveness in identification of differentially expressed genes, especially those 
transcripts expressed in low abundance (Diatchenko et aL, 1996). SSH is able to 
selectively amplify target cDNA fragments and in the meanwhile the amplification 
of non-target cDNA sequences is suppressed. Therefore, this technique has been 
chosen as an alternative approach in this research project to identify genes that are 





Materials and Methods 
Chapter 2 
Materials and Methods 
2.1 Plating out the adult human normal liver cDNA 
library 
1» 
A single colony of E. coli XLl-Blue MRF' was inoculated into 50ml of LB broth 
f< 
(1% bacto-trytone, 0.5% yeast extract, 1% NaCl) supplemented with 0.2% maltose 
and lOmM M g S O 4 and allowed to grow at 30°C. The host cell was spun down at 
2000rpm for 10 min. It was diluted to OD o^o = 0.5 with lOmM MgSO4. Then 100-
、 
150 pfu of the adult normal liver cDNA library which was purchased from 
Stratagene (Cat no. #937241) were mixed with 200fil of diluted host cells. The 
cDNA library was. The mixture was incubated at 37°C for 15 min. Then 3ml of 
NZY medium (0.5% NaCl, OJo/oMgSCVVHp，0.5% yeast extract, 1% casein 
hydrolysate) at 45-50°C containing melted 0.4% agarose were added. After gentle 
vortexing, the whole content was plated onto NZY agar plate (NZY medium with 
1.50/0 agar) and the plate was allowed to set for 10 min； The plate was inverted and 
incubated at 37�C for overnight. Plaques were picked randomly and each of them 
was resuspended in 50^il of SM (lOOmM NaCl, 9mM MgSO4, 50mM Tris-HCl, 
0.01% gelatin). The phage stocks were stored at4°C. 
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2.2 PCR amplification of cloned human normal liver 
cDNA inserts 
An aliquot (1.5^il) of each phage suspension (from section 2.1) was subjected to PCR 
in the presence of 50mM KC1, 1.5mM MgCl2, lOmM Tris-HCl，200^M of each 
dNTP, 2.5 units Taq DNA polymerase, and lOpmol of each X ZAP forward primer 
(5‘-CCAAGCTCGAAATTAACCCTCAC-3') and M13 universal primer (5'-
CGACGTTGTAAAACGACGGCCAGT-3') in a final volume of 50^il. The PCR 
A 
reaction was overlaid with 50^ il of mineral oil and subjected to 5 min denaturation at 
94�C，followed by 35 cycles ofamplification (95°C，36 sec; 54�C，36 sec; 72�C，90 
sec) and 10 min fmal extension at 72°C. The PCR product was analyzed on a 1.0 % 
* 
agarose /EtBr gel run in IX TBE buffer. 
18 
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2.3 Cycle sequencing of cloned human normal liver cDNA 
inserts 
Two and a half microlitre of unpurified PCR product was used as template directly 
for cycle sequencing. The DNA was combined with 30mM Tris-HCl (pH9.5), 
7.5mM MgCl2 2^1 Thermo Sequenase DNA polymerase (Pharmacia), and 5 pmol of 
CY5 conjugated T3 primer (CY5-5 ‘-GCTCGAAATTAACCCTCACTAAAG-3') in 
a final volume of 17.5^il. This T3 primer is nested within the primers used to amplify 
the DNA template. Then the whole reaction was divided into 4 portions (i.e., 4^1 per 
portion). Each of them was mixed with 4^il corresponding dideoxyribonucleotide 
termination mix (150^iM of each dNTP, and 1.5^iM corresponding ddNTP). 
% 
Sequencing reactions were cycled for 26 cycles at 95°C, 36 sec; 50°C, 36 sec; 72°C, 
90 sec and a 10 min final extension at 72°C. The reactions were stopped by 4^il "stop 
solution" (95% formamide，20mM EDTA and lOmg/ml blue'dextran). The 
sequencing products were stored at 4 � C before separated on 6% acrylamide gel using 
Pharmacia LKB A l . F . DNA sequencer. 
t> 
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2.4 mRNA preparation from the HCC tissue and its 
surrounding normal counterpart 
2.4.1 Human tissues for constructing subtractive libraries 
The HCC tissue and its surrounding normal counterpart were kindly provided by 
Prof C.T. Liew, Department of Anatomical and Cellular Pathology, Prince of Wales 
Hospital, Shatin, Hong Kong. The tissues were obtained from a 53 years old local 
female patient suffered from HCCand diagnosed with HBV positive. The tumor size 
was about 13 cm in diameter. The tissues were frozen and stored in liquid nitrogen 
container before mRNA preparation. 
、 
2.4.2 Isolation of mRNA using Promega PolyATtract® System 
1000 . 
Promega PolyATtract® System 1000 was used to isolate mRNA directly from tissue 
lysates. This system utilizes a synthetic biotinylated oligo(dT) probe to hybridize 
with the poly(A) sequence on the mRNA. The oligo(dT):mRNA hybrids are captured 
with Streptavidin MagneSphere® Paramagnetic Particles (SA-PMPs). And the 
purified mRNA is eluted by the addition of sterile water. 
The tissue was first ground into powder and. placed into the homogenizer, which 
containing GTC Extraction Buffer (4M guanidine thiocyanate, 25mM sodium citrate 
[pH7.1]) with 2% P-mercaptoethanol. The tissue was homogenized at high speed 
until no visible tissue fragments remained. Then the lysate was forced to pass 
2 0 
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through 21G syringe for five times in order to lyse the cell more effectively. 
Preheated Dilution Buffer (6X SSC, lOmM Tris-HCl [pH7.4], lmM EDTA, 0.25% 
SDS) at 70°C with 1% P_mercaptoethanol was added to the homogenate and mixed 
thoroughy by inversion. Two hundred and fifty picomole of biotinylated oligo(dT) 
probe was added. The reaction mixture was incubted at 70°C for 5 min and 
centrifuged at 12,000g for 10 min at room temperature. 
During the centrifugation，the SA-PMPs was completely resuspended. For each 
reaction, 3ml of SA-PMPs was aliquoted to a sterile microtube and was placed on 
the Magnetic Stand. The captured SA-PMPs were saved and the storage buffer was 
discarded. The particles were washed three times by 3 ml SSC 0.5X solution and 
finally resuspended in the same volume of SSC 0.5X solution. � 
When the centrifugation of homogenate was completed, the supernatant was saved 
and added to the tube containing the washed particles away from the Magnetic Stand. 
This ensures proper mixing of the homogenate and the particles. The reaction 
mixture was incubated at room temperature for 2 min. The particles were captured 
by the Magnetic Stand and the supernatant was discarded. Again, the particles were 
washed three times by 2ml SSC 0.5X solution. Finally, the mRNA was eluted by 
2ml sterile H2O and stored at -70°C. 




To concentrate the mRNA prepared in the previous section, ethanol precipitation was 
preformed. Sodium acetate was added to 2ml eluted mRNA of each tissue in a final 
concentration of 0.3M. The solution was mixed well and 3 volumes of ice-cold 
ethanol were added. The ethanolic solution was stored at -20°C for overnight to 
allow RNA to precipitate. Then it was recovered by centriftigation at 12,000g for 15 
min at 4°C. The supernatant was discarded and the RNA pellet was allowed to air 
dry at room temperature. Then it was washed by same volume of70% ethanol twice. 
Again the pellet was recovered by centrifugation at 12,000g fbr 15 min at 4°C. The 
pellet was air dried and resuspended in 15^il sterile H ^ . The RNA solution was 
stored at -70°C. The yield of RNA was determined by UV spectrophotometry at 
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2.5 PCR-Select cDNA subtraction 
In this part, HCC mRNA and normal counterpart mRNA was subjected to 
subtractive hybridization to identify genes up-regulated in HCC. PCR-Select cDNA 
subtraction kit from Clontech was used to carry out such subtractive hybridization to 
enrich differentially expressed cDNAs. Besides, a control cDNA subtraction was 
carried out simultaneously using human skeletal muscle mRNA provided by the kit. 
Before looking at the procedures of cDNA subtraction, its m9lecular basis would be 
discussed first. , 
2.5.1 Molecular basis of PCR-Select cDNA subtraction 
(Diatchenko et al” 1996; and Clontech's user manual) � 
First of all, cDNA is synthesized from 0.5-2.0^ig ofpoly A+ RNA from the two types 
of tissues or cells being compared. Both cDNAs are then digested with Rsal, a four-
base cutting restriction enzyme that yields blunt ends. The tester cDNA is subdivided 
into two samples, and ligated to two different cDNA adaptors individually. The ends 
of both cDNA adaptors are tailored without phosphate groups, so that only one 
strand of each adaptor attaches to the 5, ends of the cDNA. The two adaptors are 
also designed to have stretches of identical sequence to allow annealing of the PCR 
primer once the recessed ends have been filled in. 
Two rounds ofhybridization are then performed. In the first hybridization, an excess 
of driver is added to each sample of tester, i.e. the two pools of tester cDNA that 
ligated to different cDNA adaptors. Then the mixtures are heat denatured and 
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allowed to anneal, generating a, b, c, and d molecules in each sample (Figure 2.1, on 
page 36). The concentration of high- and low- abundance sequences is equalized 
among type a molecules because of faster reanneal for the more abundant molecules 
due to the second-order kinetics ofhybridization. In addition, the single strand type a 
molecules are significantly enriched for differentially expressed sequences, as 
"common" non-target cDNAs form type c molecules with the driver cDNA. 
In the second hybridization, the two primary hybridization., samples are mixed 
together without further denaturation and in the presence of a second portion of 
freshly denatured driver cDNA. During this process, only the remaining equalized 
and subtracted single-stranded (ss) cDNAs are able to reassociate and form a new 
type e hybrid. The presence of denatured driver during second hybridization further � 
enhances the formation of hybrid e for differentially expressed sequences. There is 
an unique feature on the new type hybrids e that distinguish them from other hybrids: 
they possess different adaptor sequences on their 5, ends which correspond to the 
two different cDNA adpators. Such feature allows annealing o f two different nested 
primers in order to amplify the enriched type e hybrids for the differentially 
expressed sequences. 
After the two rounds ofhybridization, the entire pool ofmolecules is subjected to an 
extension reaction to fill in the sticky ends of the molecules for primer annealing. 
And then PCR is carried out to amplify the desired differentially expressed 
sequences. During PCR amplification, type a and d molecules cannot be amplified 
since they do not have the primer binding sites. Type b molecules also unlikely to be 
amplified due to the effect of suppression PCR (Siebert et al, 1995). This occurs 
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because type b molecules have complementary sequences on each end o f a ss cDNA. 
During the primer annealing step，the hybridization kinetics strongly favor them to 
form a pan-like structure that prevents primer annealing. Despite there is a chance 
that a primer anneals and is extended, the newly formed PCR product still have 
complementary sequences on each end and thus do not favor PCR amplification. 
Type c molecules can only be amplified at a linear rate as it only possesses primer 
binding site at one end. To summarize, non-specific amplification is efficiently 
suppressed while only type e molecules that represents differentially expressed 
sequences (have two different adaptors) can be amplified exponentially. 
Another round o fPCR is carried out using nested primers to further amplify type g 
molecules (differentially expressed sequences) and reduce any background PCR 
products. At this step, cDNA subtraction is completed and the cDNAs are ready to � 
be cloned into a T/A cloning vector or site-specific cloning. The cloned subtracted 
cDNAs can then be further identified and characterized by sequence or hybridization 
analysis. Also, the uncloned cDNAs can be used as hybridization probe to screen 
libraries. This will be further discussed in the next section. 
In this project, two directions of cDNA subtraction have been carried out. For the 
forward subtraction, HCC cDNA was used as tester while its normal counterpart 
cDNA was used as driver to construct subtracted HCC cDNA library. And it is vice 
versa for the reverse subtraction. 
2.5.2 First-strand cDNA synthesis 
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Two micrograms ofeach HCC, normal liver, and the control human skeletal muscle 
mRNA were combined with 2^iM cDNA synthesis primer (5'-TTTTGTACAAGCT 
T30N,N-3') in microtubes. The final volume was adjusted to 5^il by sterile ^ 0 . The 
tubes were incubated at 70�C in a thermal cycler for 2 min. Then the tubes were 
cooled on ice for another 2 min. Each reaction was further combined with 50mM 
TYis-HCl (pH8.5), 8mM MgCl^, 30mM KC1 and lmM dithioretiol, lmM of each 
dNTP, and 20 units of AMV reverse transcriptase in a final volume of 10^1. 
Reaction tubes were incubated at 42°C for 1.5 hr in an air incubator. Then the tubes 
were place on ice to terminate the first-strand cDNA synthesis and immediately 
proceeded to the second-strand cDNA synthesis. 
% 
2.5.3 Second-strand cDNA synthesis 
The previously cooled first-strand HCC, normal liver, and the control skeletal 
muscle cDNA were subjected to second-strand cDNA synthesis in the presence of 
100mM KC1, lOmM ammonium sulfate, 5mM MgClj, 0.15mM p-NAD, 20mM Tris-
HC1 (pH7.5), and 0.05mg/ml BSA, 200^iM ofeach dNTP, 24 units DNA polymerase 
I，1 unit RNase H, and 4.8 units E. coli DNA ligase in a final volume of 80^1. The 
reaction tubes were incubated at 16�C for 2 hr. Then 6 units o f T 4 DNA polymerase 
were added to each reaction and were incubated at 16°C for further 30 min in a 
thermal, cycler. After incubation, EDTA and glycogen were added with fmal 
concentration 0.01M and 0.05mg/ml respectively to terminate second-strand 
synthesis. 
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The cDNA were purified by phenol-chloroform separation. lOO t^l of 
phenol:chloroform:isoamyl alcohol (25:24:1) was added to each reaction tube and 
vortexed thoroughly. Then they were centrifuged at 14,000rpm for 10 min at room 
temperature. The top aqueous layers were transferred to separate microtubes. The 
above separation was repeated once using lOO i^l of chloroform:isoamyl alcohol 
(24:1) was added. The top aqueous layer was saved and precipitated by ethanol 
precipitation. 40^il of 4M NH4OAc and 300^il of 95% ethanol were added to each 
reaction tube. They were vortexed thoroughly and centrifuged at 14,000rpm for 20 
min at room temperature. The supknatants were carefully removed and the pellets 
were washed by 500^il 80% ethanol with centrifugation at 14,000rpm for 10 min. 
The pellets were saved, air dried and dissolved in 50^il ofHjO. 
% 
2.5.4 Rsal digestion 
及似1 digestion was carried out with each experimental ds HCC, normal liver cDNA, 
and control skeletal muscle cDNA. The restriction enzyme digestion generates 
shorter，blunt-ended ds cDNA fragments, which are optimal for subtraction and 
necessary for adaptor ligation. 
Forty-three and a half microlitre of each tester, driver, and control skeletal muscle 
cDNA was combined with lOmM Bis Tris Propane-HCl [pH7.0], lOmM MgCl，， 
0.2mM DTT, and 15 units of Rsal in a final volume of 50^il. The tubes were 
incubated at 37°C for 1.5 hr. EDTA and glycogen were added with a final 
concentration of 0.01M and 0.05mg/ml to the reactions to terminate the reaction. 
‘ 2 7 
Materials and Methods 
The cDNAs were purified by phenol-chloroform separation. lOO i^l of 
phenol:chloroform:isoamyl alcohol (25:24:1) was added to each reaction tube and 
vortexed thoroughly. Then they were centrifuged at 14,000rpm for 10 min at room 
temperature. The top aqueous layers were transferred to separate microtubes. The 
above separation was repeated once using 100^1 of chloroform:isoamyl alcohol 
(24:1) was added. The top aqueous layer was saved and precipitated by ethanol 
precipitation. To precipitate the Rsal digested cDNA, 25^il of 4M NH4OAc and 
187.5fil of 95% ethanol were added to each reaction tube. They were vortexed 
thoroughly and centrifuged at 14,000rpm for 20 min at room temperature. The 
supernatants were carefully removed and the pellets were washed by 200^il 80% 
ethanol with centrifugation at 14,000rpm for 5 min. The pellets were saved, air dried 
、 
and dissolved in 5.5^d o f H f i . The cDNA was stored at -20�C. 
2.5.5 Adaptor ligation ‘ 
In order to perform differential screening of the subtracted library, subtractions in 
both directions for each HCC/normal liver cDNA should be carried out. The forward 
subtraction that used HCC cDNA as tester and its normal counterpart cDNA as 
driver to enrich for differentially expressed sequences present in HCC mRNA but 
not normal counterpart mRNA, and the vice versa for the reverse subtraction. 
To perform cDNA subtractions in both directions, tester cDNA corresponding to 
each of mRNA sample should be prepared. For the control subtraction, the tester 
cDNA was prepared by mixing the control skeletal muscle cDNA with 
^XllA!Haem DNA. In this section, three adaptor ligations were performed for each 
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experimental tester cDNA, as well as the control skeletal muscle cDNA. Each tester 
cDNA was subdivided into two portions, and ligated to different adaptors separately. 
After the ligation, portions of each tester tube were combined so that the cDNA was 
ligated with both adaptors. 
To prepare experimental cDNA for adaptor ligation, l|il of each Rsal-digQstQd HCC 
and normal counterpart cDNA from section 2.5.4 was diluted with 5^il ofsterile H2O. 
For control skeletal muscle cDNA, l^il of the cDNA from section 2.5.4 was mixed 
with 5^il of the diluted ^Xm/Haelll DNA (150ng/ml). Thus it contains 0.2% 
//aeIII-digested c|>X174 DNA and each fragment corresponds to about 0.02% oftotal 
cDNA. 
、 
For each experimental tester cDNA and for the control skeletal muscle tester cDNA, 
2j^l of diluted tester cDNA prepared in the previous step was combined with 2|iM 
Adaptor 1 (5'-CTAATACGACTCACTATAGGGCTCGAGCGGCCGCCCGGGCA 
G G G T - 3 1 ) , 50mM Tris-HCl [pH7.8], lOmM MgCl^, 2mM DTT, 0.05mg/ml BSA, 
and 400 units o f T 4 DNA ligase in a final volume of 10|il. This set up was repeated 
for each tester cDNA using Adaptor 2R (5'-CTAATACGACTCACTATAGGGCAG 
CGTGGTCGCGGCCGAGGT-3') instead of Adaptor 1. So, six tubes were set up. 
They were named as the following: 
T-1: HCC cDNA ligated with Adaptor 1， 
T-2: HCC cDNA ligated with Adaptor 2R, • 
N-1: normal counterpart cDNA ligated with Adaptor 1， 
N-2: normal counterpart cDNA ligated with Adaptor 2R, 
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SM-1: control skeletal muscle cDNA with 0.2% //adII-digested (j>X174 DNA 
ligated with Adaptor 1, and 
SM-2: control skeletal muscle cDNA with 0.2% 7^dII-digested c^X174 DNA 
ligated with Adaptor 2R. 
So, each tester cDNA had two ligation reactions to be carried out separately. Then 
2pl of each tester with different adaptors was mixed together in a fresh microtube. 
This is referred as unsubtracted tester control T-c, N-c, and SM-c respectively. After 
ligation, approximately 1/3 of the cDNA molecules in each unsubtracted tester 
control tube would bear two different adaptors. 
All the reaction tubes prepared in the above procedures were incubated at 16°C � 
overnight. Then the ligation reaction was stopped by adding EDTA and glycogen in 
a final concentration 25mM and 125p,g/ml respectively. Samples were heated at 
72°C for 5 min to inactivate the ligase. 1^1 of each unsubtracted tester control (T-c, 
N-c, and SM-c) was diluted into 1ml of HjO. They would be used for PCR 
amplification in section 2.5.9 The preparation of adaptor-ligated tester cDNAs was 
complete and the samples were stored at -20°C. 
2.5.6 Ligation efficiency analysis 
PCR experiment was carried out to verify that at least 25% of the cDNAs have 
adaptors on both ends. One microlitre of each diluted ligated cDNA from section 
2.5.5 was used as PCR template. For HCC and skeletal muscle adaptor-ligated 
cDNA, it was 200-fold diluted whereas normal liver adaptor-ligated cDNA was 10-
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fold diluted. Each diluted template was combined with 40mM Tricine-KOH, 15mM 
KOAc, 3.5mM Mg(OAc )2 , 3.75^ig/ml BSA, 200^M of each dNTP, 0.5^il 50X 
Advantage cDNA Polymerase Mix and 400nM each of G3PDH 3' primer (5'-
TCCACCACCCTGTTGC 
TGTAGCCAA-3') and PCR primer 1 (5'-CTAATACGACTCACTATAGGGC-3'). 
Another PCR reaction for each ligated cDNA was set up as the above condition 
except using G3PDH 5' primer (5'-ACCACAGTCCATGCCATCACTGCCA-3') 
instead o fPCR primer 1. The PCR reactions were overlaid with, 50^il mineral oil and 
incubated in a thermal cycler at 75°C for 5 min to "fills in" the missing strand of the 
adaptors. Then they were subjected to 20 cycles of amplification (94°C, 30 sec; 65°C, 
30 sec; 68°C，180 sec) immediately. The PCR products were analyzed on a 1.0 % 
agarose /EtBr gel run in IX TBE buffer. � 
2.5.7 First hybridization . 
For each o f the experimental and control skeletal muscle subtraction, 1.5^il of each 
Adaptor-1 ligated tester and Adaptor-2R ligated tester (from section 2.5.5) was 
mixed with 1.5^il of corresponding 7^tjfI-digested driver cDNA (from section 2.5.4) 
in the presence of kit-provided Hybridization buffer with IX final concentration. 
They were referred to hybridization sample 1 and 2. The reactions were overlaid 
with 50^1 of mineral oil and subjected to denaturation at 98°C for 1.5 min in a 
thermal cycler. Then they were incubated at 68°C for 8 hr. After 8 hr incubation, the 
reactions were subjected to second round hybridization without any delay. 
2.5.8 Second hybridization 
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First, l^il of corresponding driver cDNA was combined with Hybridization buffer in 
IX final concentration in a final volume of 4^1. l^il of this mixture was aliquoted to 
a sterile microtube and was overlaid with 1 drop of mineral oil. The driver cDNA 
was incubated in a thermal cycler at 98°C for 1.5 min. Entire hybridization sample 2 
and then small amount of air were drawn into a pipette tip by a micropipettor. This 
step was repeated with the tube containing the freshly denatured driver using the 
same pipette tip. It should contain both hybridization sample 2 and freshly denatured 
driver cDNA separated by a small pocket of air. The entire mixture was transferred 
to the tube containing hybridization sample 1 and mixed by pipetting up and down. 
The above procedure ensures that the two hybridization samples mix together only in 
the presence of freshly denatured driver. The reaction mixture was incubated at 68°C � 
overnight. Then 200^il of dilution buffer (20mM HEPES-HC1 [pH8.3], 50mM NaCl, 
0.2mM EDTA [pH8.0]) was added to the reaction mixture and mixed by pipetting. 
The tube was heated at 68°C for 7 min. The sample was stored at -20°C. 
It is noted that the primary hybridization samples should not be denatured during 
second hybridization and removed from the thermal cycler for longer than necessary 
to add freshly denatured cDNA. 
2.5.9 Primary PCR amplification 
Differentially expressed cDNAs were selectively amplified by two rounds of PCR 
amplification. In primary PCR amplification, only ds cDNAs with different adaptor 
sequences on each are exponentially amplified. Seven PCR reactions were set up : (1) 
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forward-subtracted HCC cDNA (T), (2) the unsubtracted tester control (T-c), (3) 
reverse-subtracted normal counterpart cDNA Q^), (4) the unsubtracted tester control 
for the reverse subtraction (N-c), (5) subtracted control skeletal muscle cDNA, (6) 
the unsubtracted tester control for the control subtraction (SM-c), and (7) the PCR 
control subtracted cDNA that provided in the kit. The PCR control subtracted cDNA 
provides a positive PCR control and contains a successfully subtracted mixture of 
//^jfelll-digested ^X174 DNA. 
it 
One microlitre of each diluted cDNA (i.e., each subtracted sample from section 2.5.8 
and the corresponding diluted unsubtracted tester control from section 2.5.5) and 
PCR control subtracted cDNA provided in the kit was used as the PCR template. It 
was combined with 40mM Tricine-KOH, 15mM KOAc, 3.5mM Mg(OAc ) 2 , � 
3.75^ig/ml BSA, 200^iM of each dNTP, 400nM PCR primer 1，and 0.5^il 50X 
Advantage cDNA Polymerase Mix in a final volume of25^1. The PCR reaction was 
overlaid with 50^il of mineral oil and incubated in a thermal cycler at 75°C for 5 min 
to "fills in" the missing strand of the adaptors. Then they were subjected to 30 cycles 
of amplification (94°C，30 sec; 66�C, 30 sec; 72°C, 90 sec) immediately. The PCR 
product was analyzed on a 1.0 % agarose /EtBr gel run in IX TBE buffer. 
2.5.10 Secondary PCR amplification 
In secondary PCR amplification, nested PCR-was carried out to further reduce 
background and enrich for differentially expressed sequences. 1^1 of each 10-fold 
diluted primary PCR mixture was subjected to PCR in the presence of 40mM 
Tricine-KOH, 15mM KOAc, 3.5mM Mg(OAc ) 2 , 3.75^ig/ml BSA, 200^iM of each 
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dNTP，0.5^il 50X Advantage cDNA Polymerase Mix, and 400nM of each Nested 
PCR primer 1 (5'-TCGAGCGGCCGCCCGGGCAGGT-3') and Nested PCR primer 
2 (5'-AGCGTGGTCGCGGCCGAGGT-3') in a final volume of 25^1. The PCR 
reaction was overlaid with 50^il of mineral oil and then subjected to 12 cycles of 
amplification (94°C，30 sec; 68�C, 30 sec; 72�C，90 sec). The PCR product was 
analyzed on a 1.0 % agarose /EtBr gel run in IX TBE buffer. The reaction mixture 
was stored at -20°C and should be enriched for differentially expressed cDNAs. 
I) 
ff 
2.5.11 PCR analysis of subtraction efficiency 
In order to evaluate the efficiency of subtraction, the abundance of G3PDH cDNA 
before and after subtraction was compared by PCR analysis. For the evaluation of � 
fonvard subtraction efficiency, ljil of each 10-fold diluted subtracted and 
unsubtracted secondary PCR products was used as the PCR template. It was 
combined with 40mM Tricine-KOH, 15mM KOAc, 3.5mM Mg(OAc ) 2 , 3.75^g/ml 
BSA，200^iM of each dNTP, 400nM G3PDH 3’ and 5，primer, and 0.5^1 50X 
Advantage cDNA Polymerase Mix in a final volume of30^il. The PCR reaction was 
overlaid with 50^1 of mineral oil and subjected to 33 cycles of amplification (94°C, 
30 sec; 65�C，30 sec; 68°C, 120 sec). 5^1 of PCR reaction aliquot was removed from 
each reaction after 13，18，23, 28, and 33 cycles. For the evaluation of reverse 
subtraction efficiency, 2-fold diluted secondary PCR products were used instead of 
10 fold diluted secondary PCR products. Also, the reactions were subjected to 38 
cycles ofamplification and PCR reaction aliquots after 18, 23, 28, 33 and 38 cycles 
were removed. All the PCR aliquots were examined on a 1.0 % agarose/EtBr gel run 
in IX TBE buffer. 
3 4 
Materials and Methods 
F i g u r e 2 . 1 Schematic diagram of PCR-Select cDNA subtraction. Type e molecules are 
formed only if the sequence is up-regulated in the tester cDNA. Solid lines represent the Rsal-
digested tester or driver cDNA. Solid boxes represent the outer part o f t h e Adaptor 1 and 2R longer 
strands and correspond to the sequence of the PCR primer used during the primary amplification. 
Clear boxes represent the inner part of Adaptor 1 and correspond to the sequence o fone o f the nested 
primer used during secondary amplification. Shaded boxes represent the inner part ofAdaptor 2R and 
correspond to the sequence of another nested primer used during secondary amplification. (Adapted 
from Diatchenko et al., 1996) 
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2.6 Construction of HCC subtracted cDNA library by T/A 
cloning method 
The secondary PCR product from the forward subtraction, which HCC cDNA was 
used as tester and normal counterpart cDNA was used as driver, was cloned in pT-
Adv vector (Clontech) by T/A-cloning method. The condition of secondary PCR 
amplification was the same as the one described in section 2.5.10 except an addition 
of 5 min final extension at 72°C. The PCR product w^^ s analyzed by gel 
electrophoresis and subjected to ligation to pT-Adv vector within a day. 3^il o f P C R 
product was added to 50^il of TOPlOF, E. coli competent cells with 20mM p-
mercaptoethanol. The ligation reaction was incubated on ice for 30 min. After 30 
min incubation, it was heated shock for exactly 30 sec in at 42°C water bath and then � 
placed on ice for 2 min. The transformed cells were recovered in the presence of 
250^d ofSOC medium (2% tryptone, 0.5% yeast extract, lOmM NaCl, 2.5mM KC1, 
lOmM MgCl2.6H2O, 20mM glucose). It was shaken horizontally at 37°C for 1 hr at 
225 rpm in a rotary shaking incubator. Then the transformed bacteria were spread on 
LB plate (LB medium in 1.5% agar, 25^g/ml X-Gal and 50^iM ofIPTG) containing 
50fig/ml ofampicilin at a suitable density for colony picking. The plate was inverted 
and incubated at 37°C for at least 18 hr. Then the plates were shifted to 4°C for 2-3 
hr to allow proper color development. 
White colonies were randomly picked and each ofthem was cultured in 100^1 of LB 
broth containing 50^ig/ml ampicilin at 37°C for overnight. The bacterial culture was 
then stored at 4°C. 
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2.7 PCR amplification of cloned subtracted cDNA 
An aliquot (1^1) of each bacterial culture (from section 2.6) was subjected to PCR in 
the presence of 40mM Tricine-KOH, 15mM KOAc, 3.5mM Mg(OAc ) 2 , 3.75^ig/ml 
BSA，200nM of each dNTP, 0.2^il 50X Advantage cDNA Polymerase Mix, and 
200nM ofeach Nested PCR primer 1 and Nested PCR primer 2 in a final volume of 
20)il. The PCR reaction was overlaid with 50^il of mineral oil and subjected to 30 
sec denaturation at 94�C，followed by 24 cycles ofamplificatiori (95°C, 30 sec; 68°C, 
3 min). The PCR product was analyzed on a 1.0 % agarose /EtBr gel run in IX TBE 
buffer. 
Other than cloned subtracted cDNAs, 2 kit-provided negative hybridization cDNAs � 
(cDNA lR and cDNA 2R) were also amplified. The condition of secondary PCR 
amplification was the same as the one described in section 2.5.10. • 
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2.8 Cycle sequencing of cloned subtracted cDNA 
The subtracted cDNA clones were subjected to cycle sequencing by either dye-
primer or dye-terminator techniques. Both of these techniques relied on 
dideoxyribonucleotide chain termination method. 
2.8.1 Dye-primer cycle sequencing (Pharmacia) 
it 
Before performing dye-primer cycle sequencing, the sequencing template was 
prepared by PCR amplification. The subtracted cDNA clones were subjected to PCR 
that have the same condition as the one mentioned in section 2.7 except the pair of 
primers and the annealing temperature used. M13 reverse primer (5'- � 
CAGGAAACAGCTATCAC-3') and M13 universal primer (5'-
CGACGTTGTAAAACGACGGCCAGT-3') were used to amplify the cDNA insert. 
The annealing temperature was decreased to 58�C so that the PCR profile became 
95°C，30 sec; 58�C, 30 sec; 68�C，270 sec for 24 cycles. 
Two and a half microlitre of unpurified PCR product was used as template directly 
for cycle sequencing. The sequencing reaction was carried as the same described in 
section 2.3 except the sequencing primer used. CY5 conjugated T7 primer (CY5-5'-
GTAATACGACTCACTATAGGGC-3') was used instead of CY5 conjugated T3 
primer. . 
2.8.2 Dye-terminator cycle sequencing (Pharmacia) 
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The experiment was carried out in a 96-well plate format. Two microlitre of 
unpurified PCR product amplified by nested PCR primer 1 and 2 from section 2.7 
was used directly as DNA template for cycle sequencing. It was subjected to 
sequencing reaction in the presence of 8 i^l ofDYEnamic ET reagent premix, lOpmol 
of nested PCR primer 1 in a final volume of 20^il. Sequencing reaction was cycled 
for 30 cycles at 95�C, 10 sec; 50°C, 15 sec; 60�C，60 sec. Ethanol precipitation was 
carried out as post-reaction cleanup before gel electrophoresis. For each reaction, 2^il 
of7.5M ammonium acetate and 2.5 volumes of 100% ethanol Were added so that the 
fmal concentration of ethanol was 70%. Then it was subjected to centrifugation at 
4,000rpm for 30 min at 14°C. The plate was inverted and was centrifuged for another 
1 min at 500rpm on a paper towel to remove supernatant. The pellet was washed by 
100^d of 70% ethanol. The plate was subjected to centrifugation at 4,000rpm for 15 
min at 14�C and then followed by an inverted spin. Then the pellet was allowed to 
air dry and resuspended in lO^il ofloading buffer (70% formamide and lmM EDTA). 
The sample was stored at 4°C before gel electrophoresis analysis on MegaBACE 
1000 DNA sequencer. 
Energy transfer technology was utilized for signal detection in automated DNA 
sequencing. Each dideoxy terminator in DYEnamic ET reagent premix was labelled 
with two fluorescence dyes. The donor dye was fluorescein. Each of the four chain 
terminators, ddG, ddA, ddT or ddC have a different acceptor dye. They are 
rhodamine 110, rhodamine-6-G, tetramethyl rhodamine, and rhodamine X. 
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2.9 Sequence analysis 
The sequences reported in this project were searched against the non-redundant 
nucleotide sequence database, which includes sequences from GenBank, EMBL, 
DDPJ and DBJ, by the BLASTN program at the National Center for Biotechnology 
Information. 
Sequence similarity identified by the BLAST program was considered statistically 
significant with an Expect value (E) smaller than e^^. The Expect value (E) is a 
parameter that describes the number of hits one can "expect" to see just by chance 
when searching a database of a particular size. Essentially, the E value describes the 
random background noise that exists for matches between sequences. � 
The results returned from the BLAST program were examined carefully to determine 
the identity ofeach clone. The data of the match with the highest score and matching 
percentage were stored in a database for further data analysis. 
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2.10 Differential screening ofHCC subtracted clones 
Though cDNA subtraction is able to greatly enrich differentially expressed 
sequences, variable amount of cDNAs that are common to both tester and driver 
(regarding as backgrounds) are inevitably present in the PCR mixture and cloned in 
the vector together with those differentially expressed sequences. Thus, instead of 
going straight to Northern blot analysis which is more time consuming and labor 
intensive，we first used EST approach to have an overview on t|>e subtracted cDNAs 
and performed a differential hybridization step which can help to rule out the false_ 
positve clones before embarking on Northern blot analysis. 
There are two approaches for differentially screening the subtracted library. The first � 
one is using labelled tester and driver first-strand cDNA as the hybridization probe to 
screen the subtracted cDNA library (Hedrick et aL, 1984; Sakaguchi et aL, 1986; 
Yang et al” 1999). The labelled tester probe will hybridize with those clones 
corresponding to differentially expressed sequences but labelled driver will not 
hybridize to them or give weaker signal intensity. However, there is a shortcoming in 
this method. Only those clones that correspond to highly abundant mRNAs (i.e., 
mRNAs that consitute at least 0.2% of total cDNA in the probe) will produce 
detectable hybridization signals (Nucleic Acid Hybridization, 1985; Wang & Brown, 
1991). Clones that correspond to low abundance differentially expressed mRNAs are 
unlikely to be detected by this approach. 
Alternatively, the subtracted library can be screened by hybridization with forward-
and reverse- subtracted cDNA probes, and the PCR amplified unsubtracted control 
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probes. The forward-subtracted probe is made from the same subtracted cDNA used 
to construct the subtracted library. For the reverse-subtracted probe, it is made with 
the original tester cDNA as a driver and the driver cDNA as a tester. Clones that 
correspond to truely differentially expressed sequences will hybridize to the forward-
subtracted probes but not the reverse-subtracted probes or produce different signal 
intensities (Lukyanov et cd., 1996; Jin et aL, 1998). The hybridization signals from 
the two PCR amplified unsubtracted control probes can provide more information to 
corroborate or disprove the subtracted probe results. As mention before, those low 
abundance differentially expressed sequences are enriched during cDNA subtraction. 
This methods can overcome the problem of inefficient detection of rare transcripts 
mentioned in the above at a cost of slightly higher false-positive rate. 
% 
In this research project，the latter approach has been employed to screen the 
subtracted HCC cDNA library in order to identify those low abundance differentially 
expressed sequences more efficiently. Also, this approach requires less RNAs for 
differential screening. 
2.10.1 cDNA inserts amplification by PCR 
Clones that were successful in DNA sequencing were chosen to undergo differential 
screening. The cDNAs used for constructing cDNA array were prepared by PCR 
amplification as described in section 2.7. 
2.10.2 Preparation of cDNA dot blots of the PCR products 
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A suitable size (12cm x 8.5cm) PVDF membranes (Millipore) was activated by 95% 
ethanol for 1-3 sec. Then it was equilibrated in sterile H ^ for 15-30 min before 
transfer of cDNA to the membrane. 
For each PCR reaction, 2.2^il of PCR product was combined with 220^il of freshly 
prepared 0.3N NaOH in a 96-well plate to denature the DNA for hybridization. PCR 
products from the two negative hybridization controls were also included. 50^il of 
each NaOH diluted PCR products were dotted on activated PVOF membrane in a 
96-well plate format. This procedure was carried out using Bio-Dot Microfiltration 
Apparatus (Bio-Rad). Each well was washed by 50^1 ofsterile H^O twice. Then the 
blot was neutralized in 0.5M Tris-HCl (pH 7.5) and washed in sterile H A It was 
、 
dried at 70°C at oven and then the DNA was cross-linked to the membrane using a 
UV linking device. Four identical blots were prepared for hybridization with both 
subtracted and unsubtracted probes. ‘ 
2-10.3 Random primer labelling of cDNA probes 
To radiolabel cDNA probes, about 200^il of each forward- and reverse-subtracted 
and their corresponding unsubtracted control cDNAs was prepared by PCR as 
described in section 2.5.10. Then each of them was concentrated by ethanol 
precipitation. For each reaction, concentrated ammonium acetate was added to adjust 
to a final concentration of 2M. Then 2 volumes of 100% of ethanol was added and 
subjected to centrifugation at 12,000g for 30 min at 16�C. The DNA pellet was then 
washed by same volume of 70% ethanol and subjected to centrifugation for further 
30 min. The DNA pellet was resuspened in 45^1 sterile 吐 0 finally. 
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The concentrated cDNA was labelled by random primer labelling method using 
Ready To Go DNA Labelling Beads (-dCTP) from Pharmacia. It was first denatured 
at 100°C for 3 min and then chilled on ice for another 2 min. The labelling bead that 
consists ofbuffer，dATP, dGTP, dTTP, FPLCpwre™ Klenow Fragment (7-12 units) 
and random oligodeoxyribonucleotides, primarily 9-mers was reconstituted with 
concentrated cDNA and 50^iCi of [a-^^P]dCTP (3000 Ci/mmol, Pharmacia). The 
final reaction volume was adjusted to 50^1. The reaction mixture was incubated at 
37°C for 30 min. 
The unincorporated [a-^^P]dCTP was removed by applying the unpurified probe into 
CHROMA SPE^TM+sTE 100 size exclusion chromatography column (Clontech). � 
The column was first centrifuged at 700g for 5 min to purge the equilibration buffer 
from the column and re-establish the matrix bed. The freshly labelled probe was 
applied to the column and centrifuged at 700g for further 5 min. The radioactively 
labelled probe was collected in the flowthrough. In general, at least 1 x 10^ cpm per 
probe could be acheived. 
2.10.4 Hybridization with cDNA probes 
PVDF membrane with dotted cDNA clones was activated in 95% ethanol for 1-3 sec 
and equilibrated in sterile HjO for 15-30 min before prehybridization. The activated 
membane was placed in a hybridization bottle and the prehybridization solution was 
added. For each membrane, the prehybridization solution was prepared by 
combining 50^il o f20X SSC (175.3g NaCl and 88.2g C^Rs^af i f lH^O at pH7.0) to 
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50^il of blocking solution (lOmg/ml sheared salmon sperm DNA and 0.3mg/ml 
oligonucleotides corresponding to the nested primers and complementary sequences). 
The mixture was boiled for 5 min and chilled on ice. Then it was added into 5ml of 
ExpressHyb)TM Hybridization Solution (Clontech). The membrane was prehybridized 
for 40-60 min with continuous agitation at 72°C in a hybridization incubator. 
The hybridization probe was prepared by mixing 50^il of20X SSC, 50^il of blocking 
solution and purified probe. The mixture was boiled for 5 min, chilled on ice and 
then added to hybridization bottle, it was allowed to hybridize at 72°C for ovemight 
with continuous agitation. Same number of cpm for each probe should be added and 
the probe was avoided to be added to the membrane directly. 
% 
After overnight hybridization, the membrane was washed four times with preheated 
low-stringency (2X SSC/0.5% SDS) washing solution at 68°C for 20 min. Then it 
was washed twice with preheated high-stringency (0.2X SSC/0.5% SDS) at 6 8 � C for 
20 min. Then the membrane was exposed to Kodak BioMax MS film for two weeks 
with an intensifying screen at -70°C. 




3.1 The sequencing results of adult human normal liver 
cDNA clones 
Five hundred adult human normal liver cDNA clones and 142,824 base pairs were 
r 
sequenced from the cDNA library. The average success rate is 67%. The average 
length of the EST sequence is 286 base pairs. The processed DNA sequences were 
sent to NCBI for homology searches using the BLASTN program. The results of the 
searches were edited and stored in a database. The database stores the information of 
each sequenced cDNA clones including its clone number, putative identity, 
accession number, sequence length of the cDNA, and the Expect value and the 
percentage of homology of the best sequence alignment. A summary of results 
obtained from our database search is shown in Table 1. 
In order to analyze the accuracy of automated DNA sequencing, 15 clones were 
randomly chosen from those 100 clones that are matched with mitochondrial 
genomes for assessment. Totally 4414 base pairs were aligned. The number of 
mismatches, insertion and deletion was counted for each hundred base. As the data 
shown in Table 2, the quality of sequencing was best closest to the primer and 
decreased gradually as the increase of sequencing length. The overall accuracy for 
the first 300 base pairs is 96.0%. Though it is slightly lower than the sequencing 
accuracy of previous EST projects (around 98-97%) reported by other research 
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groups (Adams et al., 1991; Liew et aL, 1994), this level of ambiguity still did not 
significantly affect the identification of known and previously unknown transcripts 
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Table 1 Summary of sequences and clones from the adult human normal 
liver cDNA library. 
BLASTN search result Number of clones Percentage (%) 
Human match 335 67.0 
I* 
Non-human match , 11 2.2 
Novel sequences 104 20.8 
Mitochondrial genes 50 10.0 
Grandtotal ^ f ^ 7 " 
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Table 2 Accuracy assessment using 15 clones which match with 
mitochondrial genome. 
Range of sequences Aligned bases Accuracy (%) 
(base pair) 
1 - 1 0 0 1 5 0 0 9 6 . 8 
1» 
1 0 1 - 2 0 0 产 1 4 8 3 9 5 . 7 
2 0 1 - 3 0 0 1 1 2 0 9 5 . 4 
> 3 0 0 3 1 1 9 5 . 2 
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3.2 Categorization of ESTs sequenced from the adult 
normal liver 
In the 500 cDNA clones that were sequenced, there are 335 human matches and 11 
non-human matches. In order to study the pattern of gene expression in adult human 
normal liver, these 356 ESTs were categorized according to their putative functions 
into 11 groups. They are contractile elements, cytoskeleton and related proteins, 
extracellular matrix protein, proteins involved in energy metabolism, hormones and 
It 
proteins involved in hormonal regulation, proteins that participate in signal 
transduction and cell cycle regulation, proteins of transcriptional and translational 
machinery, membrane associated proteins, secretory proteins, proteins involved in 
other metabolism and miscellaneous proteins (Table 3 and 4) as described by Liew et � 
al., 1994. 
Out of the 346 ESTs matching to known genes, two hundred and two unique known 
genes were found in total. Genes coding for secretory proteins solely make up 54% 
of genes expressed in human liver. It is followed by genes involved in other 
metabolism (16.2%), transcriptional and translational machinery (4.0%), signal 
transduction and cell cycle regulation (3.8%), membrane associated (3.5%), energy 
metabolism (2.9%), hormone and hormonal control (1.4%), cytoskeletal related 
(1.2%), and contractile elements (0.6%). None of the sequences is found to be 
coding for extracellular matrix protein. The remaining 11.8% are those genes lacking 
enough information for classification. The two major secretory proteins, serum 
albumin (HSA) and alpha-1-antitrypsin, represented 4.20% and 3.64% of all ESTs 
presented respectively. 
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Table 3 Expression profile of adult human normal liver cDNA library. 
Category Frequency Percentage (%) 
Contractile element 2 0.6 
Cytoskeletal related 4 1.2 
Extracellular matrix 0 .. 0.0 
Energy metabolism , 10 2.9 
Hormone and hormonal control 5 1.4 
Signal transduction/cell cycle regulation 13 3.8 
Transcription and translation 14 4.0 
Membrane associated 12 3.5 � 
Secretory protein 189 54.6 
Other metabolism 56 16.2 
Miscellaneous 41 11.8 
T ^ ~ ^ rooo 
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Table 4 Human liver ESTs that are matched to known genes in the 
GenBank and EMBL databases. Presented are genes that have homology with our 
collection of liver ESTs, together with accession numbers for these genes and 
number of clones from which the ESTs were derived. In cases where multiple clones 
representing a single gene exist, only a single, representative clone is given. In cases 
where ESTs matched to non-human sequences, the organism from which the 
matching sequencing was derived is also indicated in parentheses. The number of 
genes identified was stated beside each category name. 
Putative identity Accession Frequency 
1) Contractile elements (n=2) , 
Myosin L29138 1 
myosin X [5o5 taurus] U55042 1 
2) CytoskeIetal related proteins (n=4) 
actin, mutant beta- (beta'-actin) X63432 1 � 
cofilin, non-muscle type X95404 1 
nucleoporin 98 (NUP98) U41815 1 
tropomyosin, cytoskeletal TM30 (nm) X04588 1 
3) Extracellular matrix (n=l) 
none 
4) Energy metabolism ( n = l l ) 
aconitase U80040 1 
ATP synthetase beta-subunit X05606 1 
ATPase, F0/F1- gene encoding Y08620 1 
cytochrome b5 M22865 1 
cytochrome bc-1 complex core protein II J04973 1 
glycogen phosphorylase, liver Y15233 1 
isocitrate dehydrogenase, NADP-dependent (IDH) AF020038 1 
malate dehydrogenase (MDHA) . U20352 1 
malate dehydrogenase, cytosolic D55654 1 
NADH:ubiquinone oxidoreductase subunit B13 (B 13) U53468 1 
succinyl-CoA synthetase alpha subunit (SCS), alternatively spliced [Sus AF008589 1 
scrofa] 
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5) Hormones and hormonal regulation (n=3) 
Angiotensinogen X15327 3 
endothelin-converting-enzyme 1 Z35307 1 
insulin-like growth factor II located on chromosome 11 X03427 1 
6) Signal transduction and cell cycle regulation (n=12) 
ClDpro te in X95592 2 
calcineurin A2 M29551 1 
DAP-1 X76105 1 
endozepine (putative ligand of benzodiazepine receptor) RNA M15887 1 
myeloid cell differentiation protein (MCL 1) L08246 1 
potassium channel Kir 1.4，inward rectifier AB013889 1 
RAB7 protein “ x93499 1 
scaffold protein Pbpl 产 U83463 1 
TGF-beta activated kinase 1 c AB009358 1 
thymosin beta-10 M20259 1 
transport protein, liver-specific {Rattus norvegicus] L27651 1 
tumor necrosis factor type 1 receptor associated protein (TRAP1) u i 2 5 9 5 1 
% 
7) Transcription and translation (n=14) 
histone H2B AJ223353 1 
Hlark U89505 1 
hnRNP-El X78137 1 
NF-E2-like basic leucine zipper transcriptional activator Nrf2 S74017 1 
nuclear factor IV X57500 1 
ribosomal protein D23660 1 
ribosomal protein L27a U14968 1 
ribosomal protein S13 (RPS 13) L01124 1 
ribosomal protein S16 M60854 1 
r ibosomalproteinS5 U14970 1 
translation elongation factor 1-alpha (EFlA) M29548 1 
translation elongation factor G [Rattus norvegicus] L14684 1 
translation initiation factor AF012088 1 
TREB protein x55543 1 
8) Membrane associated (n=12) 
26-kDa cell surface protein TAPA-1 M33680 1 
aminopeptidase N M22324 1 
aminopeptidase-B [Rattus norvegicus] D87515 1 
CD68=110kDa transmembrane glycoprotein S57235 1 
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GDNF receptor alpha U95847 1 
gp96，human homologue of murine tumor rejection antigen X15187 1 
Ly-6-like protein (CD59) M95708 1 
MHC protein homologous to chicken B complex protein mRNA M24194 1 
p40 Y11395 1 
peroxisomal farnesylated protein (PXF) Y09048 1 
progesterone binding protein, putative AJ002030 1 
RET Fused Gene (RFG) ^77548 1 
9) Secretory protein (n=59) 
acid glycoprotein 2, alpha-1 (AGP2) M21540 1 
acid glycoprotein, alpha-1 X02544 10 
alpha-2-thiol proteinase inhibitor “ K02566 3 
antichymotrypsin, alpha-1 产 X00947 6 
antithrombin III (ATIII) gene, exon 3 LOO 187 1 
antitrypsin variant, alpha-1 X17122 1 
antitrypsin, alpha-1- K01396 13 
antitrypsin, alpha-1- (S variant) K02212 1 
apolipoprotein B-lOO M36676 1 � 
apolipoprotein CII X00568 4 
apolipoprotein H (beta 2-glycoprotein I) X58100 3 
ceruloplasmin (ferroxidase) M13699 1 
coagulation factor V M14l35 1 
complement component C l r J04080 2 
complement component C1 s, alpha- and beta-chains M18767 1 
complement component C3 (C3) J04763 5 
complement component C6 J05064 1 
complement component C9 X02176 1 
complement factor B X72875 1 
complement H factor M17517 \ 
complement-associated protein SP-40,40 alpha-1 and beta-1 chain X14723 1 
C-reactive protein X56692 3 
fibrinogen A-alpha-chain J00128 3 
fibrinogen alpha chain M64982 3 
fibrinogen alpha-subunit bipartite transcript, extended (alpha-E) variant M58569 8 
fibrinogen beta-chain J00129 10 
fibrinogen gamma A chain X02415 6 
fibrinogen gamma A chain [Mustela putorius] U28494 1 
fibrinogen gamma chain X51473 8 
fibrinogen gamma'-chain (gamma B) [B.taurus] X15556 1 
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group-specific component (GC) X03178 1 
haptoblobin (HP) [Macaca mulatto] U02036 1 
haptoglobin (Hpl) X01791 1 
haptoglobin alpha lS (Hpa lS) X00637 5 
haptoglobin alpha- and beta-chain X00606 3 
haptoglobin alpha( 1 S)-beta precursor K01763 3 
haptoglobin alpha(2FS)-beta X00442 8 
haptoglobin alpha-2 and beta subunit M12387 1 
haptoglobin Hp-alpha-2 K00422 4 
hemopexin J03048 4 
histidine-rich glycoprotein M13149 2 
HS-glycoprotein, alpha-2 (alpha and beta chain) M16961 1 
inter-alpha-trypsin inhibitor heavy chain “ M18193 1 
inter-alpha-trypsin inhibitor heavy chain H3 X67055 1 
leuserpin 2, protease inhibitor (hLS2) X03498 1 
macroglobulin, alpha-2 M36501 1 
microglobulin, alpha-1 (protein HC) X04225 3 
plasminogen M74220 3 
prealbumin, transthyretin X59498 1 � 
proline-rich protein (PRP) M31452 2 
protein C inhibitor (PCI-B) U35464 1 
prothrombin J00307 2 
serum albumin (HSA) V00495 15 
serum amyloid A (SAA) M10906 10 
serum amyloid A1 (SAA1) M23698 3 
serum amyloid P component (SAP) X04608 2 
S-protein X03168 3 
Transferrin M12530 2 
zinc-alpha2-glycoprotein D90427 2 
10) Other metabolism (n=52) 
3-ketoacyl-ACP synthase (Kas4) [Cuphea hookeriana] AF060519 1 
78 kdalton glucose-regulated protein (GRP78) (BiP) X87949 1 
alanine:glyoxylate aminotransferase D13368 1 
alcohol dehydrogenase class II (ADH4) pi subunit . M15943 1 
alcohol dehydrogenase class I (ADH2) beta-1 subunit M24317 1 
aldehyde dehydrogenase 1 (ALDH1) AF003341 1 
aldehyde oxidase (hAOX) L11005 2 
aldolase B X02747 1 
aspartate aminotransferase M37400 1 
- 5 5 
Results 
beta-galactoside alpha-2,6-sialyltransferase X62822 1 
betaine:homocysteine methyltransferase U50929 1 
beta-transducin repeat containing protein Y14153 1 
carbamyl phosphate synthetase I Y15793 2 
carnitine carrier Y10319 1 
cathepsin B L16510 2 
CYPC2C9, putative S46963 1 
cytochrome P-450 (cyp3 locus) X12387 1 
cytochrome P450 monooxygenase CYP2J2 U37143 1 
cytochrome P450 reductase S90469 1 
cytochrome P-450 S-mephenytoin 4-hydroxylase (P-450mp) M21939 1 
delta-aminolevulinate dehydratase M13928 1 
dihydropyrimidinase “ D78011 1 
enoyl-CoA: hydratase 3-hydroxyacyl-CpA dehydrogenase (EHHADH) L07077 1 
fatty acid binding protein, liver (FABP) M10050 1 
ferritin L chain Ml 1147 1 
fibroblast catalase K02400 1 
flavin containing monooxygenase 5 (FM05) L37080 1 
glutamate dehydrogenase (Glud-1, EC 1.4.1.3) X07769 1 -
glutathione S-transferase Ha subunit 2 (GST) M16594 1 
hydroxysteroid dehydrogenase, oxidative 3 alpha U89281 2 
IIC2 Y00498 1 
insulin-like growth factor binding protein 4 (IGFBP4) M62f403 1 
lanosterol 14-demethylase D55653 1 
lecithin-cholesterol acyltransferase M12625 1 
mannosidase II isozyme, alpha L28821 1 
natural killer cell enhancing factor (NKEFA) L19184 1 
nicotinamide N-methyltransferase CNNMT) U20970 1 
nucleobindin U31342 1 
phosphatidylinositol (4,5) bisphosphate 5-phosphatase homolog U45974 1 
PROS-27 X59417 1 
protein-tyrosine-phosphatase G1 D13380 1 
RNase 4 D37931 1 
sarcosine oxidase (SOX) [Oryctolagus cuniculus] U82267 1 
sec61 homologue [Canisfamiliaris] , M96629 1 
sterol/retinol dehydrogenase AF057034 2 
transglutaminase (TGase) M5 5153 1 
tRNA synthetase, alanyl- D32050 1 
tyrosine aminotransferase (TAT) (EC 2.6.1.5) X52520 1 
ubiquitin U49869 1 
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ubiquitin carboxyl extension protein S79522 1 
UDP-glucuronosyltransferase isozyme 1, bilirubin M57899 1 
11) Miscellaneous (n=32) 
l-8U gene from interferon-inducible gene family X57352 1 
23 kD highly basic protein X56932 1 
autonomously replicating sequence (ARS) L08441 1 
B cell chronic lymphocytic leukemia immunoglobulin heavy chain U22381 1 
beta2 - microglobulin, mutant (Daudi) X07621 1 
C2f U72514 1 
chaperonin X74801 1 
cytochrome oxidase subunit I (COI) and subunit II (C0I1) pseudogenes AF035429 2 
glucose 6-phosphate translocase, putative ” Y15409 1 
guanylate binding protein isoform I (GBP-2) M55542 1 
haptoglobin and haptoglobin-related protein (HP and HPR) M69197 2 
haptoglobin gene (aIpha-2 allele) and haptoglobin-related gene M10935 1 
haptoglobin related protein x89214 2 
KIAA0034 gene D21260 1 
KIAA0062 gene D31887 1 � 
KIAA0064 gene D31764 1 
KIAA0109 gene D63475 1 
KIAA0172 gene D79994 1 
KIAA0212 gene D86^67 1 
KIAA0539 gene AB011111 1 
metallothionein isoform 2 X97260 1 
mRNA clone with similarity to L-glycerol-3-phosphate:NAD U22961 5 
oxidoreductase and albumin gene sequences 
p l90-B(pl90-B) U17032 1 
progesterone receptor-associated immunophilin FKBP54 U42031 1 
pseudogene for cytochrome c-like protein, clone pHGC3K5 D00266 1 
second protein of inter-alpha-trypsin inhibitor complex X07173 1 
SYT X79201 1 
t-complex polypeptide 1 X52882 1 
TEGT X75861 1 
translationally controlled tumor protein , x i 6 0 6 4 1 
unknown protein D14446 3 
xs l3 Z36785 1 
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3.3 Adaptor ligation efficiency analysis 
For the three different tester cDNAs, it was found that the PCR products amplified 
using one gene-specific primer (G3PDH 3, primer) and PCR primer 1 were 0.75kb. 
And the PCR product amplified using two gene-specific primers (G3PDH 3, and 5' 
primers) were -0.45kb, as shown in figure 3.1. The intensity of PCR products 
depended on the abundance of G3PDH transcripts in that particular cDNA 
preparation. The normal counterpart liver tissue expressed the least G3PDH among 
three tissues as revealed by this,experiment. For each adpator-ligated tester cDNA, 
the intensity of PCR bands amplified using either one gene-specific primer or two 
gene specific primers did not differ by more than four-fold. It implied that the 
efficiency of adaptor ligation was over 25% and the adaptor ligated tester cDNAs � 
were suitable for proceeding to the hybridizations. 
I f the cDNA was not fully digested by Rsa\’ a 1.2kb band would be observed along 
with the expected 0.75kb band when the template was amplified using the G3PDH 3, 
primer and PCR 1. In my results, only 0.75kb band was observed. It confirms that 
complete Rsa\ digestion of cDNAs was performed in section 2.5.4. 
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Figure 3.1 Ethidium bromide stained agarose gel showing the results of the 
Ugation efficiency analysis. Panel A: Ligation efficiency analysis on adpator-
ligated HCC tester cDNA. Panel B: Ligation efficiency analysis on adpator-ligated 
normal liver tester cDNA. Panel C: Ligation efficiency analysis on adpator-ligated 
skeletal muscle tester cDNA. In each panel, lane 1 refers to PCR products using 
corresponding Adaptor 1-ligated tester cDNA as the template and the G3PDH 3, 
primer and PCR primer 1. Lane 2 refers to PCR products using corresponding 
Adaptor 1-ligated tester cDNA as the template and the G3PDH 3, and 5, primers. 
Lane 3 refers to PCR products using corresponding Adaptor 2R-ligated tester cDNA 
as the template and the G3PDH 3，primer and PCR primer 1. Lane 4 refers to PCR 
products using corresponding Adaptor 2R-ligated tester cDNA as the template and 
the G3PDH 3，and 5' primers. Lane M: 100bp DNA marker (MBI Fermentas). 
Panel A 
^^^H 
^^ ^^ H 
國 
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Figure 3.1 (continued) 
Panel B 
M P • 
H H 
Panel C � 
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^ n 
K^ ^^ H 
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3.4 Primary and secondary PCR Amplification 
After primary PCR amplification, ds cDNAs with different adaptor sequences on 
each end are exponentially amplified. The primary PCR products (Figure 3.2) in the 
experimental subtracted and unsubtracted samples (Lane 1-4) appeared as a faint 
smear from 0.2-2.0 kb, with or without some distinct bands upon gel electrophoresis. 
With the PCR control subtracted cDNA (Lane 7), the major bands appearing 
corresponded to the ^MAIHaeWl fragments. The pattern of PCR product of skeletal 
it 
muscle subtraction (Lane 5) alsp showed the correct iSfMA!HaelW bands whereas a 
smear appeared in that of the one of skeletal muscle unsubtracted control. 
Nested PCR was carried out to further reduce background and enrich for � 
differentially expressed sequences in secondary PCR amplification. The patterns of 
secondary PCR products were similar to those of primary PCR products (Figure 3.3). 
The experimental subtracted and unsubtracted samples (Lane 1-4) looked like smears 
with or without a number of distinct bands. On the other hand, secondary PCR 
products from the PCR control subtracted cDNA (Lane 7) and from the skeletal 
muscle subtraction (Lane 5) contained mostly DNA fragments corresponding to the 
^llAIHaeWl digest. There was a slight mobility shift of these PCR products in 
comparison with the original, digested 小174 due to the adaptor sequences on both 
ends of the DNA fragments. It was noted that the banding pattern of each 
unsubtracted tester control was different from that of that corresponding 
experimental subtracted DNA samples. 
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Figure 3.2 Ethidium bromide stained agarose gel showing the primary PCR 
products of subtracted and unsubtracted control samples. Lane 1: Primary PCR 
products of subtracted HCC tester cDNA. Lane 2: Primary PCR products of 
unsubtracted HCC tester cDNA. Lane 3: Primary PCR products of subtracted HCC 
normal counterpart tester cDNA. Lane 4: Primary PCR products of unsubtracted 
HCC normal counterpart tester cDNA. Lane 5: Primary PCR products of subtracted 
skeletal muscle tester cDNA containing 0.2% (j>174/7^eIII-digested DNA. Lane 6: 
Primary PCR products of unsubtracted skeletal muscle tester cDNA containing 0.2% 
(^174///aeIII-digested DNA. Lane 7: Primary PCR product ofPCR control subtracted 
cDNA. Lane M: 100bp DNA marker (MBI Fermentas). The white arrows on the 





Figure 3.3 Ethidium bromide stained agarose gel showing the secondary 
PCR products of subtracted and unsubtracted control samples. Lane 1: 
Secondary PCR products of subtracted HCC tester cDNA. Lane 2: Secondary PCR 
products of unsubtracted HCC tester cDNA. Lane 3: Secondary PCR products of 
subtracted HCC normal counterpart tester cDNA. Lane 4: Secondary PCR products 
of unsubtracted HCC normal counterpart tester cDNA. Lane 5: Secondary PCR 
products of subtracted skeletal muscle tester cDNA containing 0.2% isfMAIHaelll-
digested DNA. Lane 6: Secondary PCR products of unsubtracted skeletal muscle 
tester cDNA containing 0.2% ^174///aeIII-digested DNA. Lane 7: Secondary PCR 
product ofPCR control subtracted cDNA. Lane M: 100bp DNA marker (Pharmacia). 
The white arrows on the right hand side indicate the major bands of is^MAIHaelW 
digest. ‘ 





3.5 PCR analysis of subtraction efficiency 
For both directions of subtraction, there was reduction of G3PDH abundance in the 
subtracted secondary PCR product when compared to the unsubtracted secondary 
PCR product (Figure 3.4). For the HCC subtracted cDNA, a G3PDH product 
appeared after 23 cycles rather than after 18 cycles in the corresponding unsubtracted 
cDNA. It implied that there was roughly 20-fold reduction of the G3PDH fragment. 
For the normal counterpart subtracted cDNA, the G3PDH product only appeared 
it 
. after 33 cycles. However, the expected band appeared after the 18* cycle in the , 
corresponding unsubtracted cDNA and there was a more prominent reduction of 
G3PDH abundance when compared to that of HCC subtracted cDNA. Such 
difference in G3PDH reduction can be explained by its differential expression in � 
HCC and normal liver tissue (Gong et cd.，1996) or differences in subtraction 
efficiency in the two directions of subtraction. 
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Figure 3.4 Ethidium bromide stained agarose gel showing reduction of 
G3PDH abundance by PCR-Select subtraction. Panel A: PCR performed on 
HCC subtracted (Lanes 1-5) or unsubtracted (Lanes 6-10) secondary PCR product. 
Lanes 1 & 6: 13 cycles; Lanes 2 & 7: 18 cycles; Lanes 3 & 8: 23 cycles; Lanes 4 & 9: 
28 cycles; Lanes 5 & 10: 33 cycles. Panel B: PCR performed on normal counterpart 
subtracted (Lane 1-5) or unsubtracted (Lane 6-10) secondary PCR product. Lanes 1 
& 6: 18 cycles; Lanes 2 & 1.. 23 cycles; Lanes 3 & 8: 28 cycles; Lanes 4 & 9: 33 






3.6 The sequencing results of subtracted HCC cDNA 
clones 
Six hundred and fifty nine subtracted HCC cDNA clones was sequenced from the 
cDNA library. The average success rate is 70% and 244,939 base pairs have been 
sequenced. 113 clones were sequenced by Pharmacia ALF DNA sequencer whereas 
the remains were sequenced by MegaBACE automated DNA sequencer. The 
average length of the sequences is 371 base pairs. The processed DNA sequences 
it 
were sent to NCBI for homology searches using the BLASTN program. The results 
of the searches were edited and stored in a database. The database stores the 
information of each sequenced cDNA clones including its clone number, putative 
identity, accession number, sequence length of the cDNA, the Expect value and the � 
percentage of homology of the best sequence aligment. A summary of results 
obtained from our database search is shown in Table 5. 
In order to analyze the accuracy of automated DNA sequencing, 15 clones were 
randomly chosen from those 20 clones that are matched with mitochondrial genomes 
for assessment. Totally 4,878 base pairs of DNA sequences were aligned. The 
number of mismatches, insertion and deletion was counted for each hundred bases. 
The overall accuracy for the first 300 base pairs is 98.3%. As the data shown in 
Table 6，the quality of sequencing was best for the first 300 base pairs. The accuracy 
deCreased dramatically for two to three folds in the sequence beyond the first 300 
base pairs. This accuracy level falls within the range of accuracy that were reported 
by other research groups (Adams et cd., 1991; Liew et al., 1994). This level of 
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ambiguity did not significantly affect the identification of known and previously 










Table 5 Summary of sequences and clones from the subtracted HCC 
cDNA library. 
BLASTN search result Number of clones Percentage (%) 
Human match 486 73.8 
Non-human match 4 •‘ 0.6 
Novel sequences 产 149 22.6 
Mitochondrial genes 20 3.0 




Table 6 Accuracy assessment using 15 cDNA sequences which match with 
mitochondrial genome. 
Range of sequences Aligned bases Accuracy (%) 
(base pair) 
1-100 1499 97.9 
II 
101-200 1388 99.0 
ff 
201-300 822 98.0 
>300 1169 94.1 
100 clones were sequenced by dye-primer sequencing described in section 2.8.1. 




3.7 Categorization of ESTs sequenced from the subtracted 
HCC cDNA library 
In the 659 subtracted cDNA clones that were sequenced, there are 486 human 
matches and 4 non-human matches. These 490 ESTs were categorized according to 
their putative functions into 11 groups as mentioned in section 3.2 (Table 7 and 8). 
Relative frequency of known ESTs for each gene found in a HCC cDNA library and 
in a surrounding normal liver cDNA library (Kok et aL, submitted and unpublished 
II 
data) was also listed for comparison. It should be noted that the tissue samples used 
to construct the two cDNA libraries mentioned in the above are same as the two used 
to construct the subtracted cDNA library presented in this project. 
、 
Two hundred and thirty nine unique known genes were presented in total. It was 
found that the pattern of the ESTs in the subtracted HCC cDNA library was very 
different from that of normal liver cDNA library. Genes involved in other 
metabolism (36.9% of all genes represented) appeared most frequent instead of 
secretory proteins (9.6%). It is followed by genes involved in transcriptional and 
translational machinery (13.7%), extracellular matrix (10.0%), signal transduction 
and cell cycle regulation (7.6%), energy metabolism (4.7%), membrane associated 
(4.70/0)，cytoskeleton system (0.8%), hormone and hormonal control (0.4%), and 
contractile elements (0.2%). The remaining 11.4% are those genes lacking enough 
information for classification. Stearoyl-CoA desaturase, a protein under this category, 
represents 11.6% of known gene matches. The second most frequent EST appeared 
is fibronectin that belongs to extracellular matrix proteins. However, the status of 
7 0 
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differential expression of these genes remains to be confirmed by differential 









Table 7 Functional categorization of subtracted HCC cDNA clones 
represented. 
Category Frequency Percentage 
m _ 
Contractile element 1 0.2 
Cytoskeletal related 4 “ 0.8 
Extracellular matrix 严 49 10.0 
Energy metabolism 23 4.7 
Hormone and hormonal control 2 0.4 
Signal transduction/cell cycle regulation 37 7.6 
Transcription and translation 67 13.7 � 
Membrane associated 23 4.7 
Secretory protein 47 9.6 
Other metabolism 181 „ 36.9 
Miscellaneous 56 11.4 
T ^ 4 % 1 ^ 
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Table 8 Subtracted HCC ESTs that are matched to known genes in the 
GenBank and EMBL databases. Presented are genes that the subtracted HCC 
ESTs matched to, together with accession numbers for these genes and the number 
of the clones from which the ESTs were derived. In cases where multiple clones 
representing a single gene exist, only a single, representative clone is given. In cases 
where ESTs matched to non-human sequences, the organism from which the 
matching sequencing was derived is also indicated in parentheses. The number of 
genes identified was stated beside each category name. Frequency of known ESTs 
for each gene found in the HCC cDNA library (total 4173 ESTs) and the surrounding 
normal liver cDNA library (total 2973 ESTs) were listed in parallel. For example, 
dihydrodiol dehydrogenase was tagged 17 times in 4173"ESTs from HCC cDNA 
library but 1 time in 2973 ESTs from surrounding normal liver cDNA library. 
Frequency in Frequency in Frequency in 
T» ^ i . . , , . , L . subtracted HCC cDNA surrounding 
Putative identity Accession H C C c O N A ub normaiiiver 
Ub cDNA lib 
total=490~~total=4173~~total=2973 � 
1) Contractile elements (n=l) 
tropomyosin, skeletal muscle alpha- (hTM-alpha) M19715 1 0 0 
2) Cytoskeletal related (n=4) ‘ 
actin, beta (ACTB) NM_001101.2 1 4 4 
spectrin, beta, non-erythrocytic 1 (SPTBN1) NM_003128.1 1 0 0 
transgelin 2 NM_003564.1 1 5 3 
tropomyosin TM30, cytoskeletal X04588 1 2 0 
3) Extraceliualr matrix (n=4) 
cadherin 1，E-cadherin (epithelial) (CDH 1) NM_004360.1 2 0 0 
fibronectin (FN precursor) X02761.1 21 17 5 
galectin 4 (lectin, galactoside-binding, soluble, 4) NM_00614 14 3 3 
(LGALS4) 
Osteopontin M83248 12 1 0 
4) Energy metabolism (n=19) 
2,4-dienoyl CoA reductase 1, mitochondrial NM_001359.1 2 0 0 
(DECR1) 




ATP synthase X83218.1 1 1 1 
ATP synthase, H+ transporting, mitochondrial F1 NM_001686.1 1 0 0 
complex, beta polypeptide (ATP5B) 
cytochrome c oxidase subunit VIb (COX6B) NM_001863.2 1 6 0 
electron-transfer-flavoprotein, alpha polypeptide NM_000126.1 1 0 0 
(glutaric aciduria II) (ETFA) 
enolase 1, (alpha) (EN01) NM_001428.1 1 2 1 
fructose-l,6-biphosphatase (FBP1) U21931 1 0 0 
glyceraldehyde-3-phosphate dehydrogenase M17851.1 2 8 8 
hinge=OXPHOS system complex III S61826 1 6 0 
mitochondrial subunit 
hydroxyacyl-Coenzyme A dehydrogenase/3- NM_000183.1 1 0 1 
ketoacyI-Coenzyme A thiolase/enoyl- “ 
Coenzyme A hydratase (trifunctional 
protein), beta subunit (HADHB) 
isocitrate dehydrogenase 3 (NAD+) beta (IDH3B) NM_006899.1 1 0 0 
lactate dehydrogenase A (LDHA) NM_005566.1 2 5 1 
malate dehydrogenase 1，NAD (soluble) (MDH 1) NM_005917.1 1 0 0 
phosphate carrier protein, mitochondrial X60036.1 1 1 0 � 
phosphoglucomutase 1 (PGM1) NM_002633.1 1 0 0 
phosphoribosyl pyrophosphate synthetase 2 NM—002765.1 1 0 0 
(PRPS2) 
triosephosphate isomerase 1 (TPI1) NM_000365.1 1 ‘ \ 2 
ubiquinol-cytochrome c reductase binding protein NM_006294.1 1 0 0 
(UQCRB) 
5) Hormone and hormonal control (n=2) 
deiodinase, iodothyronine, type I (DI01) NM_000792.2 1 0 0 
kininogen M11438.1 1 7 9 
6) Signal transduction and cell cycle regulation 
(n=27) 
ADP-ribosylationfactor-like 1 (ARL1) NM_001177.2 1 0 0 
annexin II (Iipocortin II) (ANX2) NM_004039.1 3 3 0 
Bcl2, p53 binding protein Bbp/53BP2 U58334.1 1 0 0 
(BBP/53BP2) 
Calcyclin J02763.1 2 0 0 
calmodulin (CALM2) U94728.1 1 4 1 
calmodulin binding protein 1 [mouse] NP_033921.1 1 0 0 
CD24 signal transducer M58664 4 0 0 
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cyclin G U53328.1 1 0 0 
focal adhesion kinase (FAK) L13616.1 1 0 0 
GDP dissociation inhibitor 2 (GDI2) NM_001494.2 1 1 0 
heme-regulated initiation factor 2-alpha kinase AF181071.1 1 0 0 
(HRI) 
inhibitorofgrowth 1 (ING1) NM_005537.1 1 0 1 
Nck-associatedprotein 1 CNapl) AB014509.1 1 0 0 
pl8protein J04991 1 0 0 
p66shc (SHC) U73377.1 2 0 0 
PDZ domain containing 1 (PDZK1) mRNA, and NM_002614.1 1 0 0 
translated products 
Protein inhibitor of activated STAT X (PIASX- NM_004671.1 1 0 0 
BETA) .. 
protein tyrosine phosphatase type IVA, member 1 NM 003463.1 1 0 0 
产 一 
(PTP4A1) 
RAB13, member RAS oncogene family (RAB13) NM_002870.1 1 0 0 
S100 calcium-binding protein AlO (annexin II NM_002966.1 2 5 1 
ligand, calpactin I’ light polypeptide (pl 1)) 
(S100A10) � 
SDK3, nuclear protein AF112222.1 1 2 0 
serine/threonine kinase (BTAK) AF011468.1 1 0 0 
signal recognition particle 19kD (SRP19) NM_003135.1 1 0 0 
thymosin beta-4 M17733.1 1 ‘ 22 8 
TIAR, nucleolysin M96954.1 1 0 0 
tyrosine 3-monooxygenase/tryptophan 5- NM_003406.1 3 0 1 
monooxygenase activation protein, zeta 
polypeptide (YWHAZ) 
von Hippel-Lindau tumor suppressor (VHL) gene AF010238.1 1 0 0 
7) Transcription and translation (n=41) 
activating signal cointegrator 1 AF168418.1 1 0 0 
ERGB transcription factor M98833.3 1 0 0 
fibrillarin (FBL) NM_001436.1 1 1 0 
H2A histone family, member Z (H2AFZ) X52317 6 0 1 
H3 histone, family 3A Mn353 2 3 1 
heterogeneous nuclear ribonucleoprotein A2/B1 NM_002137.1 1 0 0 
(HNRPA2B1) 
heterogeneous nuclear ribonucleoprotein K NM_002140.1 1 3 \ 
(HNRPK) 
histone RNA hairpin-binding protein Z71188 1 0 0 
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hXBP-1 transcription factor L13850.1 2 0 0 
NSl-binding protein (NSl-BP) NM_006469.1 1 0 0 
polyadenylate binding protein II Z48501 1 0 0 
ribosomal protein D23660 1 2 3 
ribosomal protein L13 (RPL13) NM_000977.1 1 3 5 
ribosomal protein L27 (RPL27) NM_000988.1 1 15 3 
r ibosomalproteinL3 M90054.1 1 6 4 
ribosomal protein L31 (RPL31) NM_000993.1 2 13 6 
ribosomal protein L32 (RPL32) NM_000994.1 1 16 6 
ribosomal protein L39 (RPL39) NM—001000.1 1 14 5 
ribosomal protein L7 X52967 4 6 2 
ribosomal protein S l l (RPS11) NM_001015.1 2 24 6 
ribosomal protein S13 (RPS13) NM_001017.1 “ 1 8 2 
ribosomal protein S15a (RPS15A) , NM_001019.1 2 5 5 
ribosomal protein S18 X69150.1 1 27 12 
ribosomal protein S23 (RPS23) NM_001025.1 1 11 5 
ribosomal protein S25 (RPS25) NM_001028.1 1 5 5 
ribosomal protein S27 AJ001134 1 0 0 
ribosomal protein S27a (RPS27A) NM_002954.1 1 4 1 � 
ribosomal protein S4, X-linked (RPS4X) NM_001007.1 1 7 8 
ribosomal protein S7 (RPS7) NM_001011.1 3 11 2 
ribosomal RNA, 28S M11167.1 2 3 1 
small nuclear ribonucleoprotein D1 polypeptide NM_006938.1 1 ‘ 0 0 
(16kD) (SNRPD1) 
staufen (Drosophila, RNA-binding protein) NM_004602.1 1 0 0 
(STAU) 
TATA box binding protein (TBP)-associated NM_003187.1 1 0 0 
factor, RNA polymerase II, G, 32kD 
(TAF2G) 
transcription factor IID X97999 1 0 0 
translation elongation factor 1-alpha (EFlA) J04617 11 24 13 
translation elongation factor 1-gamma NM_001404.1 1 6 2 
translation initiation factor 2B-epsilon U23028.1 1 0 0 
translation initiation factor 3，subunit 10 (theta, NM_003750.1 1 0 0 
150/170kD) (EIF3S10) . 
translation initiation factor 3, subunit 7 NM_003753.1 1 0 0 
tRNA synthetase, asparaginyl- O^ARS) NM_004539.1 1 0 0 
tRNA synthetase, glycyl- (GARS) NM_002047.1 1 0 0 
8) Membrane associated (n=19) 
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adipose differentiation-related protein (ADFP) NM_001122.1 1 8 0 
ATP cassette binding transporter 1 (ABC 1) AF165281 • 1 1 0 0 
ATP-binding cassette, sub-family D (ALD), NM_002858.1 1 0 0 
member 3 (ABCD3) 
canalicular multispecific organic anion U49248 1 0 0 
transporter 
caveolin 2 (CAV2) NM_001233.1 1 0 0 
insulin receptor L07782.1 1 0 0 
integral membrane protein, calnexin, (IP90) L10284.1 2 0 0 
integrin, beta 1 (fibronectin receptor, beta NM_002211.1 1 0 1 
polypeptide, antigen CD29 includes MDF2, 
MSK12) (ITGB1) 
laminin receptor 1 (67kD, ribosomal protein SA) NM_002295.1 “ 1 0 0 
(LAMR1) 产 
membrane cofactor protein X59408.1 1 0 0 
organic anion transport polypeptide 2 AF205071 1 0 0 
outer membrane receptor Tom20 (TOM20) AF126962.1 1 0 0 
peroxisomal 70 kD membrane protein M81182 1 0 0 
peroxisomal famesylated protein (PXF) NM_002857.1 1 0 0 � 
RET Fused Gene (RFG) X77548.1 2 0 0 
translocaseTiml7a,mitochondrialinner AF106622 1 0 0 
membrane preprotein 
translocon-associated protein gamma (signal NM_007107.1 1 ‘ 1 1 
sequence receptor, gamma) (SSR3) 
vol tage-dependentanionchannen(VDACl) NM_003374.1 3 0 0 
voltage-dependent anion channel 3 AF038962 1 3 0 
9) Secretory protein (n=26) 
apolipoprotein B-lOO (apoB) M19828.1 1 5 9 
apolipoprotein C-I (AP0C1) NM_001645.2 2 17 78 
apolipoprotein C-II (APOC2) NM_000483.2 1 22 41 
apolipoprotein H NM_000042.1 1 13 15 
apolipoprotein M AF118393.3 3 0 0 
Calumenin AF013759 1 0 0 
carboxylesterase, liver ,M55509.1 1 8 4 
ceruloplasmin (ferroxidase) M13536.1 4 0 1 
complement component 1 NM_001734.1 1 0 0 
complement component 4-binding protein, alpha NM_000715.1 2 0 2 
(C4BPA) 
complement factor B X72875.1 4 1 5 
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complement H factor M17517 2 2 1 
haptoglobin (HP) NM_005143.1 1 0 3 
haptoglobin alpha lS (Hpa lS) X00637.1 2 5 25 
histidine-rich glycoprotein (HRG) NM_000412.1 1 0 5 
leuserpin 2, protease inhibitor (hLS2) X03498 1 0 0 
microglobulin, beta-2- (B2M) AF072097 1 5 7 
plasma protease (C1) inhibitor M13656.1 1 0 1 
protein S (alpha) (PR0S1) NM_000313.1 1 0 0 
retinol binding protein (RBP) X00129 1 3 0 
selenoprotein P, plasma, 1 (SEPP1) NM_005410.1 1 6 7 
serum albumin (HSA) V00494.1 2 19 235 
SPARC (osteonectin) (secreted protein, acidic, NM_003118.1 2 0 0 
cysteine-rich) 
S-protein (vitronectin) , X03168.1 1 22 25 
tissue factor pathway inhibitor (lipoprotein- NM_006287.2 1 1 0 
associated coagulation inhibitor) (TFPI) 
transferrin M12530 8 8 15 
10) Other metabolism (n=52) � 
acyl-CoA synthetase 4 (ACS4) AF030555.1 11 0 0 
adenosine deaminase, RNA-specific (ADAR) NM_001111.1 1 0 0 
aldehyde dehydrogenase (ALDH1) M31994 8 11 2 
aldehyde dehydrogenase, microsomal (ALD10) U46689.1 1 0 0 
aldehyde reductase J04794.1 3 1 1 
aldo-keto reductase AF052577 13 3 0 
aldo-keto reductase family 1, m e m b e r B l l NM_004812.1 8 3 0 
beta-hexosaminidase beta chain M19735 1 0 1 
crystallin, zeta (quinone reductase) (CRYZ) NM_001889.1 2 0 1 
dihydrodiol dehydrogenase NM_001353.2 7 17 1 
dihydropteridine reductase (hDHPR) X04882 1 0 0 
epoxide hydrolase J03518.1 3 0 1 
farnesyl diphosphate synthase (farnesyl NM_002004.1 1 3 1 
pyrophosphate synthetase, 
dimethylallyltranstransferase, 
geranyltranstransferase) (FDPS) • 
fatty acid binding protein, liver (L-FABP) M10617 1 0 6 
ferritin H chain M11146.1 7 35 6 
ferritin L chain Y09188 2 415 40 
FK506-binding protein 3 (25kD) (FKBP3) NM_002013.1 1 0 0 
flavin-containing monooxygenase 3 (FM03) Z47552 2 0 1 
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glutamine synthetase in tumorous liver S70290 3 0 1 
glutathione S-transferase A2 NM_000846.1 1 3 2 
glyoxalase I (GL01) NM_006708.1 1 0 0 
IMP (inosine monophosphate) dehydrogenase 2 NM_000884.1 1 0 1 
(IMPDH2) 
isopentenyl-diphosphate delta isomerase (IDI1) NM_004508.1 1 0 0 
lipoamide dehydrogenase J03490 1 0 0 
lysosomal acid lipase U08464 1 0 0 
lysozyme (LYZ) NM_000239.1 2 2 0 
mannosidase II isozyme, alpha L28821.1 1 0 0 
microsomal triglyceride transfer protein large NM_000253.1 1 0 0 
subunit (MTP) 
monoamine oxidase B (MAOB) NM_000898.1 “ 1 0 0 
mutL homolog 1 (MLH1) , NM_000249.1 1 0 0 
NAD(P)H menadione oxidoreductase J03934 4 2 0 
NAD(P)H:quinone oxidoreductase M81600. 1 1 0 
NAD(P)H:quinone oxidoreductase (NQ02) U07736.1 1 0 0 
NADP dependent leukotriene b4 12- D49387.1 1 8 0 
hydroxydehydrogenase � 
phenylalanine hydroxylase (PAH) NM_000277.1 1 0 1 
phosphatidylethanolamine binding protein, D16111 2 3 6 
human homologue of rat 
procollagen-lysine, 2-oxoglutarate 5-dioxygenase NM_000935.1 3 ‘ 0 0 
(lysine hydroxylase) 2 (PLOD2) 
prostaglandin F synthase AB018580.1 6 0 0 
proteasome (prosome, macropain) subunit, alpha NM_002788.1 2 0 0 
type, 3 (PSMA3) 
proteasome (prosome, macropain) subunit, alpha NM_002790.1 3 0 0 
type, 5 (PSMA5) 
proteasome subunit X D29011 1 0 0 
ribonucleaseHl (RNASEH1) NM_002936.1 1 0 0 
stearoyl-CoA desaturase (SCD) AF097514.1 57 0 4 
superoxide dismutase, Cu/Zn (S0D1) L44139.1 1 13 6 
superoxide dismutase, manganese X65965 1 0 1 
thioredoxin reductase 1 (TXNRD1) .NM_003330.1 1 0 0 
thyroid autoantigen 70kD (Ku antigen) S38729 1 0 1 
transketolase L12711.1 2 0 0 
ubiquitin-conjugating enzyme UbcH2 Z29331.1 1 0 0 
UDP-glucose 6-dehydrogenase AJ007702.1 1 0 0 




UDP-glucuronosyltransferase, liver microsomal Y00317.1 1 2 0 
(UDPGT) 
11) Miscellaneous (n=44) 
1.1 kb mRNA upregulated in retinoic acid treated U09196.1 1 0 0 
HL-60 neutrophilic cells 
78 kdalton glucose-regulated protein (GRP78) AJ271729 3 11 0 
(BiP) 
angiopoietin-related protein 3 (ANGPTL3) AF152562.1 2 0 0 
B-cell receptor associated protein (hBAP) U72511 1 0 0 
chaperonin containing TCP-1 epsilon subunit AB022158.1 1 0 0 
{Mus musculus] “ 
chaperonin containing TCP-1, subunit 8 (theta) NM_006585.1 1 0 0 
(CCT8) 
chaperonin hTRiC5, cytoplasmic U17104 1 0 0 
clathrin, heavy polypeptide-like 2 NM_004859.1 1 0 0 
colon carcinoma laminin-binding protein J03799 1 14 6 
DEAD/H (Asp-Glu-Ala-Asp/His) box NM_001358.1 1 0 0 � 
polypeptide 15 (DDX15) 
dendritic cell protein (GA17) NM_006360.1 1 0 0 
developmentally regulated protein [Rattus L20319.1 1 0 0 
norvegicus] 
E2IG3 (E2IG3) AF191018.1 1 0 0 
GTPase, nucleolar L05425 1 0 0 
guanine nucleotide binding protein (G protein), NM_006098.1 2 0 0 
beta polypeptide 2-like 1 (GNB2L1) 
heat shock lOkD protein 1 (chaperonin 10) NM_002157.1 1 4 2 
(HSPE1) 
heat shock 60kD protein 1 (chaperonin) (HSPD 1) NM_002156.1 5 0 0 
heat shock 90kD protein 1, beta (HSPCB) NM_007355.1 1 0 0 
heat shock protein 90 D87666.1 2 5 0 
host cell factor homolog LCP AF113131 1 0 0 
immature colon carcinoma transcript 1 (ICT1) NM_001545.1 1 0 0 
IRLB . X82333 2 0 0 
L3 pigment (L3) NM_013384.1 1 4 1 
La protein J04205 1 0 0 
leukocyte cell-derived chemotaxin 2 (LECT2) NM_002302.1 1 0 1 
megakaryocyte stimulating factor (MSF) NM_005807.1 1 0 1 
MEGF9 (high-molecular-weight proteins with AB011542 1 0 0 
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multiple EGF-like motifs) 
M-phase phosphoprotein homolog AF100742.1 1 0 0 
multiple inositol polyphosphate phosphatase AF084943.1 1 0 0 
N-ethylmaleimide-sensitive factor (NSF) AF102846.1 1 0 0 
nucleophosmin-retinoic acid receptor alpha U41743.1 1 0 0 
fusion protein NPM-RAR short form 
polyubiquitin UbC AB009010 1 8 0 
prefoldin subunit 2 AF117237 1 4 0 
prostate cancer overexpressed gene 1 (P0V1) NM_003627.1 1 0 0 
putative tumor suppressor AF156165.1 1 0 0 
pyrroline-5-carboxylate synthase long form U76542.1 1 0 0 
(P5CSL) 
ribosomal protein L5 pseudogene U66589 “ 2 0 0 
syntaxin binding protein 3 (STXBP3) NM_007269.1 1 0 0 
T-cell activation protein (PGR1) AF116272.1 1 0 1 
TCP1 (t-complex-1) ring complex, polypeptide 5 NM_005998.1 2 0 0 
(TRIC5) 
thyroid receptor interacting protein 15 (TRIP15) NM_004236.1 1 0 0 
tomoregulin AB004064.1 1 0 0 � 
ubiquitin A-52 residue ribosomal protein fusion NM_003333.1 1 9 4 
product 1 (UBA52) 
zinc finger protein216 (ZNF216) NM_006007.1 1 0 0 
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3.8 Differential screening of subtracted cDNA Clones 
About 260 subtracted cDNA clones listed in Table 8 were screened by PCR 
amplified subtracted and unsubtracted control probes in both subtraction directions. 
Results of differential hybridization were shown in Figure 3.6. It was found that the 
negative hybridization controls did not hybridize to the cDNA probes; and many 
clones did not hybridize to either the forward- or reverse subtracted cDNA probes. 
That means the level of background was acceptable. The radioactive signals on the 
ii 
film were measured by densitometer (Molecular Dynamics) for further data analysis. 
Different combinations of hybridization signal for each of the four probes were 
interpreted by the guidelines listed in Table 9. 
To summarize the interpretation guidelines, those subtracted clones hybridized to the 
forward-subtracted and unsubtracted tester probes but not to the reverse-subtracted 
or unsubtracted driver probes; or hybridize only to forward-subtracted probe; or 
hybridized to both subtracted probes but with 5-fold difference are strong candidates 
for differential expression. Among about 260 clones screened, at least 68 of them 
(not including novel sequences that shown differential hybridization signal) were 
found to meet the criteria mentioned above and they were listed in Table 10. 
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Figure 3.6 Results of differential hybridization. Differential hybridization 
results of three sets of dot blots were shown. Each set of dot blots was hybridized 
with cDNA probes made from either forward-subtracted cDNA (HCC as tester, 
normal counterpart liver as driver) (blot Al, B1, and C1), reverse-subtracted cDNA 
(normal counterpart liver as tester, HCC as driver) (blot A2, B2, and C2), PCR 
amplified unsubtracted HCC cDNA (blot A3, B3, and C3), or PCR amplified 
unsubtracted normal counterpart cDNA (blot A4, B4, and C4) independently. On 
each membrane, the following two clones correspond to controls. H11: Negative 
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Figure 3.6 (continued) 
BlotB 
B1. Subtracted HCC cDNA probe B2. Subtracted normal counterpart cDNA probe 
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Figure 3.6 (continued) 
BlotC 
C1. Subtracted HCC cDNA probe C2. Subtracted normal counterpart cDNA probe 
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C3. Unsubtracted HCC cDNA probe C4. Unsubtracted normal counterpart cDNA probe 
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Table 9 Guidelines for the interpretation of differential screening results. 
(Adapted and modified from Clontech's user manual) 
Type of Probe 
Forward- Reverse- Unsubtr. Unsubtr, I n t C r D r e t a t i o n ‘ 
subrt. subtr. tester driver ^ 
+ _ + _ Clones that hybridize to the forward-subtracted and 
unsubtracted tester probes but not to the reverse-subtracted or 
unsubtracted driver probes almost always (95% probability) 
correspond to differentially expressed genes, (e.g. blot A, 
clone B1 in figure 3.6) “ 
产 
+ - — - Clones that hybridize only to forward-subtracted probe are 
strong candidates for differential expression. These clones 
typically correspond to low abundance transcripts which 
were enriched during the subtraction. In most cases 
enrichment is a result of differential expression, but it can 
occasionally be an artifact, (e.g. blot A, clone D2) 
+ - + + Clones that hybridize to the forward-subtracted probe and 
both subtracted probes but not the reverse-subtracted probe 
may be difficult to interpret. Many of these cDNAs may be 
only artifactually enriched. In some cases, Northern analysis 
shows that the clone hybridizes to both the tester and driver 
RNA, but either (1) the transcripts have different sizes and 
are probably alternatively spliced forms, or (2) several 
different transcripts are identified with one or more bands 
specific to the tester RNA. The latter is often the case for 
genes that are members of multi-gene families, (e.g. blot A, 
clone F5) 
+ = Signal is observed (++ = strong signal) 
- = N o signal is observed 
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Table 9 (continued) 
Type of Probe 
Forward- Reverse- Unsubtr. Unsubtr. I n t e f D r e t a t i o n 
subrt. subtr. tester driver 
+ + + + + or - Clones that hybridize to both subtracted probes, but with 
different intensities. When the difference in signal intensity is 
greater than 5-fold, a clone (e.g. blot A, clone D5) probably 
corresponds to a differentially expressed gene. However, 
when the difference in signal intensity is smaller than 3-fold, 
the explanation is most likely a random fluctuation in the 
efficiency of the forward and reverse subtractions. Generally, 
fT 
you can use the results of the unsubtracted probes to 
corroborate or disproved the subtracted probe results. 
+ + + + Clones that hybridize equally to both subtracted probes and 
to both unsubtracted probes are definitely not differentially 
expressed, (e.g. blot A, clone B7) 
_ 一 一 _ Clones that do not have a detectable hybridization signal for 
either of the subtracted probes usually represent very low 
bundance transcripts. These low abundance cDNA fragments 
are randomly present in the subtracted library as single 
copies. Because these molecules are present at such low 
levels in the subtracted probe, they do not hybridize to the 
corresponding clone. In such cases, their differential 
expression status cannot be determined, (e.g. blot A, clone 
F8) 
+ = Signal is observed (++ = strong signal) 
- = N o signal is observed 
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Table 10 Strong candidates of differential expression in HCC identified by 
differential screening 
78 kdalton glucose-regulated protein (GRP78) (BiP) 
acyl-CoA synthetase 4 (ACS4) 
aldehyde dehydrogenase (ALDH1) 
aldo-keto reductase 
aldo-keto reductase family 1，member B11 
annexin II (lipocortin II) (ANX2) 
apolipoprotein M 
cadherin 1’ E-cadherin (epithelial) (CDH1) 
calcycIin 
ceruloplasmin “ 
cyclin G , 
dendritic cell protein (GA17) 
dihydrodiol dehydrogenase 
enolase l , (a lpha) (EN01) 
fatty acid binding protein, liver (L-FABP) 
ferritin L chain � 
fibrillarin (FBL) 
fibronectin (FN precursor) 
guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 (GNB2L1) 
H2A histone family, member Z (H2AFZ) ‘ 
H3 histone, family 3A (H3F3A) 
heat shock lOkD protein 1 (chaperonin 10) (HSPE1) 
heat shock 90kD protein 1，beta (HSPCB) 
heme-regulated initiation factor 2-alpha kinase (HRI) 
histone RNA hairpin-binding protein 
hXBP-1 transcription factor 
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase (trifunctional protein), beta subunit (HADHB) 
IMP (inosine monophosphate) dehydrogenase2 (IMPDH2) 
integral membrane protein, caInexin, (IP90) 
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, 
MSK12) (ITGB1) . 
isocitrate dehydrogenase 3 (NAD+) beta (IDH3B) 
isopentenyl-diphosphate delta isomerase (IDI1) 
lactate dehydrogenase A (LDHA) 
lysosomal acid lipase 
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membrane cofactor protein 
microglobulin, beta-2- (B2M) 
microsomal triglyceride transfer protein large subunit (MTP) 
monoamine oxidase B (MAOB) 
NAD(P)H menadione oxidoreductase 
NADP dependent leukotriene b4 12-hydroxydehydrogenase, partial cds 
organic anion transport polypeptide 2 
osteopontin 
p66shc (SHC) 
peroxisomal 70 kD membrane protein 
prostaglandin F synthase 
prostate cancer overexpressed gene 1 (P0V1) 
proteasome (prosome, macropain) subunit, alpha type, 3 (PSMA3), 
proteasome subunit X 
protein inhibitor ofactivated STAT X (PIASX-BETA) 
protein tyrosine phosphatase type IVA, member 1 (PTP4A1) 
ribosomal protein L32 (RPL32) 
ribosomalprotein S l l (RPS11) 
ribosomal protein S13 (RPS13) 
% 
ribosomal protein S4, X-linked (RPS4X) 
stearoyl-CoA desaturase (SCD) 
superoxide dismutase, Cuy'Zn (S0D1) 
superoxide dismutase, manganese ^ 
TATA box binding protein (TBP)-associated factor, RNA polymerase II，G, 32kD 
(TAF2G) 
T-cell activation protein (PGR1) 
TCP1 (t-complex-1) ring complex, polypeptide 5 (TRIC5) 
transketolase (tk) 
translation elongation factor-l-gamma 
triosephosphate isomerase 1 (TPI1) 
tRNA synthetase, asparaginyl- CNARS) 
tropomyosin, skeletal muscle alpha- (hTM-alpha) 
UDP-glucuronosyltransferase (UGT1) gene isozyme, exon 5 
UDP-glucuronosyltransferase, liver microsomal (UDPGT) 





4.1 Characterization of the ESTs generated from human 
normal liver cDNA library 
Large-scale random sequencing of cDNA libraries proyides an efficient approach to 
generate ESTs for revealing the expression profiles in different tissues or cell types. 
Results generated form cataloguing ESTs and comparing the expression profiles of 
normal and diseased tissues (in our case, normal liver and HCC) can identify up- or 
down-regulated genes can be easily identified and provide insight into the genes 
involved in the pathogenesis ofHCC. 
In this project, 500 cDNA clones from a human normal liver cDNA library were 
sequenced. The sequences were searched against GenBank/EMBL database by 
BLAST program at NCBI. Among these 500 cDNA sequences, 346 of them 
exhibited significant matches to known genes and the remainder (154 clones) 
demonstrated either matched to mitochondrial genome or did not match with any 
entry in GenBank/EMBL database (Table 1). The human and non-human matched 
sequences were classified into 11 groups according to the function of the identified 
gene products. The percentage composition of each category was listed in Table 3. It 
is not surprising that secretory protein category is the most abundant category in 
normal liver tissue since normal hepatocytes have to synthesize large varieties of 
secretory proteins in order to maintain homeostasis. Among all the clones sequenced, 
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serum albumin that plays an important role in transportation of various molecules 
and control of extracellular fluid distribution is the most abundant clone found. The 
proportion of ESTs for other metabolism category is also very high and this finding 
reflects the fact that liver is the major organ responsible for excretion and 
detoxification of the end-products of metabolism. 
When the distribution of ESTs in normal liver, HCC, and the normal counterpart 
liver cDNA libraries (Kok et al., submitted and unpublished data) were listed and 
It 
compared (Table 11), the changes in expression profile could provide some hints to 
r 
the mechanism of hepatocarcinogenesis. As expected, the proportion of secretory 
proteins was most abundant in normal liver (54.6%) but there was a significant 
decrease in HCC surrounding non-tumor tissue (43.1%) and HCC tissue (18.3%). 
、 
Such great drop in secretory protein synthesis reflects the fact that hepatocytes lose a 
number of cellular functions including synthesis of secretory proteins during the 
development ofhepatocarcinoma. 一 
On the other hand, the expression of several groups of genes were found to be 
increased in HCC and in its surrounding normal tissue in the 346 clones presented. 
One of them is the other metabolism category. In normal liver, it comprises 16% of 
total ESTs presented. The composition increased to 20% when the normal liver was 
transformed to HCC. Such slight increase may be due to a relatively higher 
metabolic rate and an increase of metabolism complexity in the actively dividing 
cancer cells. When looking into this category, it was found that several kinds of 
antioxidant proteins emerged in HCC but not in normal liver. Those include 
antioxidant protein 2, glutathione peroxidase and Cu/Zn superoxide dismutase. Such 
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antioxidant proteins may be relevant to the survival of cancer cells and provide a hint 
to explain why cancer cells can be resistant to some anti-cancer drugs by expressing 
these proteins. 
Proteins that participate in transcription and translation machinery were also up-
regulated in HCC. Its composition in normal liver is merely 4%, but increased to 
16% in surrounding non-tumor tissue and it was further boosted to 30% in HCC 
tissue. It is reasonable that HCC shows an enhanced expression of transcription and 
1» 
translation related proteins because cancer cells have to synthesize large varieties 
产 
and amounts of proteins to support its active cell division and complex metabolic 
pathways. Taking ribosomal proteins as an example, they were tagged 5 times in 500 
ESTs from normal liver cDNA library but 350 times in 2,973 ESTs and 1,029 times 
% 
in 4,173 ESTs from surrounding non-tumor liver cDNA library and HCC cDNA 
library respectively. Previous reports also pointed out the overexpression of several 
types of ribosomal proteins and translation elongation factors in HCC or other 
tumors (Adams et al., 1992a; Chester et al., 1989; Ou et al, 1987; Denis et al., 1993; 
Chassin et al, 1994; Edmonds et al., 1996; Mimori et al, 1995). Such increased 
expression in basic transcription and translation machinery proteins reflects the great 
demand on protein synthesis in the progress of HCC development. Moreover, it 
seems that HCC exhibited expression of a wide range of transcription factors 
including oncogenes c-myc and L-myc which are expressed in normal liver. Further 
studies of ESTs from the normal liver cDNA library must be carried out in order to 
confirm this finding. 
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When focusing on the extracellular matrix proteins, it is obvious that none of them 
was expressed in normal liver but many of them could be found in HCC tissue (0.8%) 
and its surrounding normal counterpart (0.4%). As extracellular matrix proteins play 
an important role in cell differentiation, proliferation or cell-cell interactions, so it is 
not surprising that there was a gradual increased expression during the progress of 
hepatocarcinogenesis. Galectin-4, one of the extracellular matrix proteins that 
modulate cell-cell and cell-matrix interactions, was tagged in both HCC cDNA 
library and normal counterpart cDNA library. Previous reports have shown that 
it 
galectin-4 was overexpressed in HCC tissue by differential display technique 
r 
(Kondoh etal” 1999). 
Finally, transcripts that encoded energy metabolism related proteins were also up-
、 
regulated in HCC tissue (6.1%) when compared to the normal counterpart (3.9%) 
and normal liver (2.9%). Such findings is reasonable based on the fact that cancer 
cells generally are more active than normal cells. Thus, the/consumed much more 
energy than normal cells in order to fulfill their active metabolic rate for its survival. 
In our laboratory, we have carried out an EST sequencing project to study three 
different cDNA libraries: (1) human adult normal liver cDNA library, the one 
presented in this research project; (2) human HBV-induced HCC cDNA library; and 
(3) surrounding non-tumor tissue cDNA library (Kok et aL, submitted and 
unpublished data). Besides looking at the global changes of expression profiles in 
these three cDNA libraries, we aim at identifying more genes that are differentially 
expressed in HCC using computational-based anaylsis (in silico Northern analysis). 
Their potentials to be tumor markers, especially HCC markers, are going to be 
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verified by other tissue samples of HCC at different stages of carcinogenesis. Being 
good candidates, they should be able to reflect the progress of carcinogenesis in 
order to become novel diagnostic markers. Though it is very difficult to use one 
single marker for effective diagnosis of a particular cancer, a combination of several 
markers will surely enhance the sensitivity and specificity of the diagnosis. 
Moreover, the EST sequencing project can provide information about a whole set of 
genes involved (up-regulated) during hepatocarcinogenesis. Such information will be 
surely beneficial for future studies in discovering the underlying principle of HBV-
“ 
induced hepatocarcinogenesis. Apart from studying genes up-regulated in HCC, this 
r 
approach can be easily extended for discovering genes that are down-regulated and 
to screen the remaining ESTs that have no known gene matches. 
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Table 11 Functional categorization of EST sequenced from 4 different 
cDNA libraries: (1) human normal liver cDNA library (shown in 
Table 3); (2) human surrounding non-tumor liver cDNA library; 
(3) human HCC cDNA library; and (4) subtracted HCC cDNA 
library (shown in Table 7). 
normal HCC surrounding subtracted 
non-tumor H C C 
normal 
Category ( ^ ( ^ ( ^ (%) 
Contractile element 0.6 0.2 0.2 0 2 
Cytoskeletal related 1.2 1.4 • \2 o.8 
Extracellular matrix 0.0 0.8 0.4 10.0 
r 
Energy metabolism 2.9 6.1 3.9 4.7 
Hormone and hormonal 1.4 o.8 1.1 0.4 
control 
Signal transduction/cell 3.8 4.8 2.7 7 6 
cycle regulation 、 
Transcription and 4.0 30.3 15.9 13.7 
translation 
Membrane associated 3.5 2.0 3.6 4 7 
一 
Secretory protein 54.6 18.3 43.1 9.6 
Other metabolism 16.2 20.6 14.7 36.9 
Miscellaneous 11.8 14.7 13.2 11.4 
Total (total no. of ESTs) 100.0 (346) 100.1 (4173) 100.0 (2973) 100.0(490) 
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4.2 EST analysis on subtracted HCC cDNA clones 
The recent development of SSH has allowed an efficient approach for the isolation 
of cDNA clones differentially expressed in two RNA populations (Diatchenko et al.， 
1996). This method was employed to identify genes differentially expressed in HBV-
induced HCC in this project. Though Northern blot analysis is the most direct and 
reliable method to verify SSH-generated subtracted clones, it is inefficient and 
tedious for high throughput screening especially when the expression level of the 
1» 
transcript is very low. As reported by other researchers, the percentage of clones in 
the subtracted library that corresponds to differentially expressed mRNAs greatly 
variable from 95% to 5% (Diatchenko et al., 1996; Gurskaya et al, 1996; Wong et 
cd., 1996). Thus, screening steps must be carried out to reduce the background. Sin^e 
high throughput EST sequencing is well developed in our laboratory, this technique 
has been exploited to study the subtracted HCC cDNA library in order to have an 
overview on the cDNAs in the whole subtraction library before we go straight into 
the differential screening step. Unlike hybridization-based methods, EST approach 
also allowed analysis on subtracted cDNA generated by SSH regardless of their 
expression level. 
EST analysis on SSH-generated subtracted library can save the time-consuming and 
costly sequencing efforts with the more abundant transcripts commonly expressed in 
“both HCC and its normal counterpart. It was found that the composition of 
subtracted HCC cDNA is very different from that of HCC cDNA library and its 
normal counterpart cDNA library (Table 11). For most ofthe functional categories in 
HCC cDNA library, it was found that their compositions in subtracted HCC cDNA 
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library were decreased significantly. On the other hand, extracellular matrix proteins 
and proteins involved in other metabolisms were greatly enriched from 0.8% to 10 % 
and 20.6% to 36.9% respectively in the subtracted library. Such drastic changes are 
due to the removal of genes that are not differentially expressed and the 
normalization of differentially expressed transcripts during the subtraction. When 
further looking at the most frequent ESTs tagged in HCC cDNA library and 
subtracted HCC cDNA library (Table 12), they were totally different in these two 
libraries. Part of them (6 out of 10) that were tagged in the HCC cDNA library were 
t» 
totally absent in the subtracted HCC cDNA library as revealed by EST sequencing. 
产 
This implied certain extent of subtraction has indeed occurred concerning these 
transcripts. Combining with the results of PCR analysis of subtraction efficiency 
(Section 3.5), these findings provides essential, though not sufficient, evidence that 
the SSH procedure successfully suppressed the cDNAs common to both HCC and its 
normal counterpart tissue. 
In addition, the probability to identify rare but important transcripts related to 
hepatocarcinogenesis was enhanced after the elimination of those abundant and 
commonly expressed transcripts. A large proportion of transcripts found in the 
subtracted library is neither expressed in HCC cDNA library nor in normal 
counterpart cDNA library. It is especially prominent in the category of ESTs 
representing genes corresponding to signal transduction or cell cycle regulation and 
• membrane associated proteins. Furthermore, a rich variety of ESTs related to gene 
transcription has been emerged in the subtracted library. These findings are in line 
with the thought that critical factors for hepatocarcinogenesis are probably signal 
transduction proteins or proteins related to gene transcription. By means of extensive 
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literature search, a large number of known tumor-related disease genes were 
identified in the subtracted HCC EST data set. These include genes identified by 






Table 12 Most frequently expressed genes in HCC cDNA library and 
subtracted HCC cDNA library. The percentage in the bracket 
represents the relative frequency of that ESTs in the corresponding 
library. 
HCC cDNA library subtracted HCC cDNA library 
ferritin L chain (9.26%) stearoyl-CoAdesaturase (SCD) (8.48%) 
ribosomal protein S21 (1 • 81 %) , fibronectin (FN precursor) (3.18%) 
ribosomal protein S19 (1.68%) galectin 4 (2.12%) 
apolipoprotein CIII (1.62%) aldo-keto reductase (1.96%) 
23kD highly basic protein (1.42%) osteopontin (1.81%) 
ribosomal protein S27 (1.10%) elongation factor 1 alpha (1.81%) 
ribosomal protein S20 (0.97%) acyl-CoA synthetase 4 (ACS4) (1.67%) � 
ribosomal protein L28 (0.97%) transferrin (1.21 %) 
apolipoprotein CII (0.91%) aldo-keto reductase family 1，member B l l 
(1.21%) 
thymosin beta-4 (0.84%) aldehyde dehydrogenase (ALDH1) (1.21%) 
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Table 13 Known tumor related genes represented in the subtracted HCC 
EST data set. 
A. Genes associated with HCC References 
adenosine deaminase, RNA-specific (ADAR) Kobayashi et al., 1993 
aldehyde dehydrogenase (ALDH1) Richmond et al., 1995 
aldehyde reductase Takahashi et al., 1995 
ATP cassette binding transporter 1 (ABC1) Furuya et al., 1997 
ATP synthase, H+ transporting, mitochondrial F1 complex, beta Cuezva et al., 1997 
polypeptide (ATP5B) 
beta-hexosaminidase beta chain Hultberg et al., 1995 
canalicular multispecific organic anion transporter ,‘ Minemura et al., 1999 
CD24 signal transducer Huang and Hsu, 1995 
产 
ceruloplasmin Casaril et al., 1989 
dihydrodiol dehydrogenase Burczynski et al, 1999 
enolase 1, (alpha) (EN01) Durany et al., 1997 
epoxide hydrolase Moody et al., 1992 
galectin 4 (lectin, galactoside-binding, soluble, 4) (LGALS4) Kondoh et al., 1999 � 
glutamine synthetase in tumorous liver Christa et aL, 1994 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Gong et al., 1996 
hXBP-1 transcription factor Kishimoto et al., 1998 
integrin, beta 1 (ITGB1) ‘ Nejjari et al., 1999 
laminin receptor 1 (67kD, ribosomal protein SA) (LAMR1) Zheng et al., 1997 
membrane cofactor protein Kinugasa et al., 1999 
microglobulin, beta-2- (B2M) Rashid et al., 1981 
p 18 protein Ghosh et al., 1993 
protein tyrosine phosphatase type IVA, member 1 (PTP4A1) Diamond et al., 1994 
SPARC (osteonectin) (secreted protein, acidic, cysteine-rich) Le Bail et al., 1999 
S-protein (vitronectin) Kondoh et al., 1999 
UDP-glucuronosyltransferase, liver microsomal (UDPGT) Hietanen et al., 1991 
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Table 13 (continued) 
B. Genes associated with other tumors References 
annexin II (lipocortin II) (ANX2) Nygaard et al., 1998 
Bcl2, p53 binding protein Bbp/53BP2 (BBP/53BP2) Mori et al., 2000 
calcyclin Brinck etal., 1995 
calmodulin (CALM2) Liu et al., 1996 
colon carcinoma laminin-binding protein Mafune et al., 1990 
complement H factor Kinders et al., 1998 
cyclin G Reimer et al., 1999 
fatty acid binding protein, liver (L-FABP) Suzuki et al., 1990 
it 
focal adhesion kinase (FAK) Agochiya et al., 1999 
glyoxalase I (GL01) 广 Ranganathan and Tew., 1993 
heterogeneous nuclear ribonucleoprotein A2/B1 (HNRPA2B 1) Fielding et al., 1999 
immature colon carcinoma transcript 1 (ICT1) van Belzen et al., 1998 
IMP (inosine monophosphate) dehydrogenase 2 (IMPDH2) Nagai et al., 1992 
insulin receptor Webster et al., 1996 
、 
lactate dehydrogenase A (LDHA) Shim et al., 1997 
nucleophosmin-retinoic acid receptor alpha fiision protein NPM- Redner et al., 1996 
RAR short form 
osteopontin Brown et al., 1994 
p66shc — Jackson et al., 2000 
polyubiquitin UbC Finch et al., 1992 
prostate cancer overexpressed gene 1 (P0V1) Cole et al., 1998 
RET Fused Gene (RFG) Santoro et al., 1994 
ribosomal protein L3 Adams et al., 1992b 
ribosomal protein L31 (RPL31) Chester et aL, 1989 
ribosomal protein S13 (RPS 13) Denis et al., 1993 
ribosomal protein S18 Chassin et al., 1994 
serine/threonine kinase (BTAK) Zhou et al., 1998 
thymosin beta-4 Yamamoto et al., 1993 
tissue factor pathway inhibitor (lipoprotein-associated coagulation Iversen et al., 1998 
inhibitor) (TFPI) 
transcription factor IID Wada et al., 1992 
translation elongation factor 1-alpha (EFlA) Edmonds et al., 1996 
translation elongation factor 1-gamma Mimori et al., 1996 
ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52) Kanayama et al., 1991 
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4.3 Candidate genes differentially expressed in HCC 
Unlike other subtraction methods, SSH dramatically increases the probability of 
obtaining differentially expressed sequences that are low in abundancy in the 
original mRNA population because of the normalization during the subtraction 
procedure (Diatchenko et al” 1996 & 1999). However, traditional differential 
screening method using labelled probes synthesized as first-stranded cDNA from 
tester and driver would be a problem to detect the low-abundance transcripts. 
it 
Previous research found that about one third of 751 SSH-generated clones showed 
no detectable hybridization signals in traditional screening method (Chim et al., in 
press). Thus, subtracted cDNA probes that show reduced probe complexity were 
used to hybridized with subtracted clones in order to increase the sensitivity of 
differential screening. 
Among about 260 genes subjected to differential hybridization, at least 68 of them 
were found to be candidate genes that are differentially expressed in HCC (Table 10). 
These clones either hybridize with only forward-subtracted probe or hybridize with 
both subtracted probes with at least 5-fold difference in signal intensity. Meanwhile, 
the results of both unsubtracted control probes were compared side by side in order 
to corroborate or disprove those artifactually enriched clones. While Northern blot 
analysis and reverse transcription-polymerase chain reaction (RT-PCR) were 
‘unde rway to confirm the differential expression status of these genes in our hands, 
we have searched the literature to support the differential expression of at least some 
of the known genes and to set up our priorities of investigation among the 
considerable number of candidates. 
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4.3.1 Established markers of HCC development 
It is not surprising that some clones in our hands are established markers of 
hepatocarcinogenesis. Membrane cofactor protein (MCP or CD46), which is one of 
the complement regulatory proteins, has been identified as one of the candidate 
genes that shown differential expression during differential hybridization (blot B, 
clone B1). Previous report has shown that the expression of this membrane-bound 
It 
protein can protect cells from complement-mediated cytotoxicity in both liver 
r 
cirrhosis and chronic hepatitis infection. Immunohistological analysis revealed that 
MCP was distributed mainly in the basolateral membrane of the hepatic cord in non-
cancerous liver, along with endothelial cells and bile duct cells. In HCC, the protein 
% 
was observed on the membrane in a non-polarized fashion (Kinugasa et al., 1999). 
The overpression of MCP in HCC cells during hepatocarcinogenesis may grant them 
the ability to escape from tumour-specific complement-mediated cytotoxicity. 
Human X-box binding protein-1 (hXBP-l), a CREB/ATF family transcription factor, 
is one of the clones that only hybridized to the subtracted HCC cDNA probe in 
differential screening step (blot A, clone F12). Its rat homolog, rHTF, was first 
identified to be involved in rat HCC (Kishimoto et al., 1996). Latter on hXBP-1 was 
also found to be abundant in the human liver and specifically stimulated in human 
. H C C but not in other types of cancers (Kishimoto et al., 1998). Injection of anti-
hXBP-1 antibody may lead to a decrease in the growth rate of cultured HCC cells. 
Though its precise role in hepatocarcinogenesis was not yet well characterized, it 
was found to be essential for liver growth and can regulate the expression of alpha-
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fetoprotein and other acute phase proteins (Reimold et al., 2000). As alpha-
fetoprotein may promote cell growth in the liver and induction of acute phase 
proteins represents liver-specific gene activation, hXBP-1 was thought to be 
involved in the growth and survival ofhepatocytes. 
Member 1 of protein tyrosine phosphatase type IVA (PTP4A1) encoding by PRL-1 
gene is another strong candidate identified by differential screening (blot B, clone 
E8). Indeed, PRL-1 mRNA elevation throughout the major proliferation phase of 
It 
liver regeneration and in other proliferating cells including fetal liver and hepatoma 
产 
cell lines was first reported by Diamond and his co-workers (Diamond et al., 1994). 
This enzyme was found to be located in the cell nucleus and able to dephosphorylate 
phosphotyrosine substrates. Moreover, PRL-1-transfected cells showed altered 
% 
growth characteristics, morphology and a transformed phenotype. As an early 
growth response gene, its transcription increased in the rat liver remnant within a few 
minutes after partial hepatectomy and largely explained thr increase in steady-state 
PRL-1 mRNA in the first few hours post-hepatectomy (Peng et al., 1999). Although 
its precise function is not yet well characterized, much evidence suggested that it is 
involved in cell signalling leading to cell growth and even hepatocarcinogenesis. 
4.3.2 Signal transduction protein 
• Annexin II is a calcium and phospholipid binding protein and a substrate for protein-
tyrosine kinases. Recent investigations have revealed involvement of annexin II in 
DNA synthesis and cell proliferation and increased levels of annexin II observed in 
cancer cells and tissues, such as glioma cells and pancreatic carcinoma cells 
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(Vishwanatha et al., 1993; Nygaard et aL, 1998). During the studies on a) hepatocyte 
proliferation after carbon tetrachloride-induced liver damage, (b) hepatocyte 
regeneration after partial hepatectomy and (c) postnatal development of hepatocytes, 
Masuki et al found that the amount of annexin II protein was increased in 
proliferative or regenerating hepatocytes (Masaki et al., 1994). This result is 
consistent with our finding as annexin II is one of the candidate genes up-regulated 
in HCC (blot A, clone B5). However, the significance of this finding on development 
of chronic liver disease or even HCC needed further investigation. 
it 
产 
Expression of calcyclin (S100A6)，a member of the S100 family and of Zn^^-binding 
proteins was found to be elevated in a number of malignant tumors (Brinck et al., 
1995; Komatsu et al., 2000). Though its function is unknown, it is generally 
、 
considered as a cell-cycle related genes by regulating Ca:+ homeostasis (Mueller et 
aL, 1999). The overexpression of calcyclin may interfere the cell cycle through 
alteration of Ca^^ homeostasis. In addition, it was found that it can interact with 
various annexins. Up-regulation of both calcyclin and annexin II as identified by 
differential screening suggested their involvement in hepatocarcinogenesis (blot A, 
clone C3). However, their precise functions on HCC development should be under 
further investigation. 
Cyclin G is one of the clones that exclusively hybridized with the forward-subtracted 
probe (blot A, clone C12). It was initially identified as a target gene of p53 tumor 
suppressor protein (Tamura et al., 1993; Okamoto and Beach D, 1994) and its p53-
dependent activation was proposed to regulate the cell cycle negatively (Shimizu et 
al, 1998; Okamoto and Prives, 1999). However, ectopic overexpression of cyclin G 
1 0 5 
Discussions 
in human RKO colon carcinoma cells was found to accelerate cell growth (Smith et 
cd., 1997) and p53-independent up-regulation of cyclin G was observed during nerve 
cells regeneration (Morita et cd., 1996). This evidence suggests that p53-independent 
cyclin G expression may be related to cell proliferation and tumor development. 
Reimer and his co-workers demonstrated that cyclin G is overexpressed in breast 
cancer tissues and cell lines, independent of p53 status (Reimer et al., 1999). Its 
expression level was found to be tightly regulated in normal breast cells and is 
peaking at the S and G2/M phases of the cell cycle with lower levels in G1. However, 
it 
the cell cycle-dependent expression was absent in breast cancer cells. The 
r 
deregulation of cyclin G expression may interfere with the cell cycle and contribute 
to tumorigenesis. 
’ 
4.3.3 Extracellular matrix proteins 
Integrins are cell surface transmembrane glycoproteins which perform receptor 
functions in cell interactions with the extracellular matrix and cell-cell contacts. 
Another function of integrins is its involvement in signal transduction that mediates 
the effects of the matrix on the physiological activity of cells, such as motility, 
proliferation, and differentiation. In our differential screening analysis，integrin beta 
1 (CD29) was found to be one of the candidate genes that are up-regulated in HCC 
(blot A, clone G12). Being one of the integrin common chain, it is related to cancer 
progression and metastasis in HCC and other cancers (Vihinen et al., 2000; Fujita et 
al., 1995). Though its expression was also observed in surrounding non-tumor tissue, 
its activity was found to be relatively higher in metastatic HCC (Jaskiewicz and 
Chasen., 1995). However, tumor progression and metastasis are usually related to 
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elevation of other integrins but not integrin beta 1 alone. Previous researches 
reported that expression of integrin oc6pi, which is essential for the attachment of 
HCC cells to lamin, plays an important role in cancer cell adhesion and migration 
fNejjari et aL, 1999; Torimura et aL, 1999). Moreover, elevation of integrin beta 1, 
which may not be specific to HCC, was thought to be related to metastasis to a 
certain extent. 
Osteopontin (OPN), a secreted adhesive glycoprotein, is significantly overexpressed 
M 
in a variety of experimental models of malignancy (Brown et al., 1994). As one of 
产 
the candidate genes we have identified (blot B, clone C7), it is generally considered 
to be associated with malignant transformation. It has been proposed that OPN 
provides an adhesive matrix suitable for tumor cell survival and invasion by 
facilitating interaction with cell surface receptors between tumor cells and tumor 
stroma (in review, Sanders et al., 1998). Recent report on its interaction with CD44 
receptor also revealed their contribution in cell migration, tumor invasion and 
metastasis, probably through CD44-dependent chemotaxis (Weber et al, 1996). 
4.3.4 Proteins involved in energy metabolism 
It is not surprising that we have fished out lactate dehydrogenase A (LDH-A) after 
differential screening (blot B, clone A3). It is well known that cancer cells rely on 
glycolysis for energy supply and are therefore less dependent on oxygen while 
normal cells undergo anaerobic glycolysis only when deprived of oxygen. Enhanced 
expression of LDH-A was achieved in cancer cells in order to increase the lactate 
acid for their survival. (Csako et aL, 1982; Kawamoto, 1994; Vila et al., 2000). 
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Recent studies have also pointed out that LDH-A gene is a c-Myc-responsive gene 
and its overexpression is necessary for c-Myc-mediated transformation (Shim et al., 
1997). 
Glyceraldehyde-3 -phosphate dehydrogenase (G3PDH) is one of the important 
enzymes in the glycolytic pathway. As mentioned before, the glycolytic pathway 
was activated in most cancer cells since they heavily relied on glycolysis to release 
energy for their survival. So it is not surprising that this enzyme was one of the 
candidate genes we have fished out (blot B，clone H3). Indeed, the results of 
r 
subtraction efficiency analysis also pointed out the possibility of G3PDH differential 
expression in HCC tissues. In a previous study, G3PDH mRNA levels in HCC were 
found to be significantly higher (14 to 16 times) than those in adjacent non-HCC and 
、 
normal liver tissues from all of the 8 patients as revealed by Northern blot analyses 
(Gong et al., 1996). It further implies that G3PDH may not be a suitable control gens 
for Northern blot analysis or RT-PCR involving HCC and its matched normal tissue. 
4.3.5 Transcription and translation machinery 
Elongation factor 1-gamma (EF1 gamma) was also found to be another candidate 
overexpressed in HCC (blot C, clone C5). It has been reported to be overexpressed in 
the malignant tissues of pancreas (Lew et al., 1992), stomach (Mimori et al., 1995), 
oesophageal carcinoma (Mimori et al, 1996), etc. Actually, it is responsible for the 
binding of aminoacyl tRNA to the ribosome with hydrolysis of guanosine 
triphosphate (GTP). During cell division, EF1 gamma is phosphorylated as a major 
substrate for P34, one of the maturation promoting factors, which is related to the 
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product of the gene cdc2 (Janssen et al., 1991). And EF1 beta gamma delta complex 
was thought to be responsible for G2 to M cell cycle transition. Therefore, it is 
proposed that the activation of cell cycle, caused by overexpression o f E F l gamma, 
may thus induce the overgrowth of neoplastic tissue. Though this hypothesis and the 
significance of overexpression o fEF l gamma in carcinoma tissue have to be further 
clarified, it is generally accepted that its overexpression is somehow involved in 
cancer development. 
tt 
Overexpression of ribosomal protein S13 in human colorectal cancer is well 
r 
described by Denis et al., 1993. Its overexpression was originally identified in rat 
colon cancer. Good correlation between its expression level and the growth rate has 
been shown in the tumor cells. Further studies found that the expression level of 
% 
human ribosomal protein S13 was also elevated in human colon cancer. It was 
suggested that the expression of this protein in the cancer cells may be related to 
their aggressiveness of invasion. Although this protein was identified upon 
differential hybridization (blot B, clone G2) and may be overexpressed in HCC, its 
significance in HCC development has to be further characterized. 
4.3.6 Proteins related to other metabolism 
In coincidence to the finding in EST analysis, ferritin L chain was also one of the 
candidate genes identified in differential screening (blot A, clone E l ) that was 
overexpressed in HCC (Kok et al, submitted and unpublished data). Its role was first 
characterized by its co-operation with ferritin H chain in iron uptake (Levi et al., 
1992). A recent study found that ferritin L chain, together with hsp70, can have 
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cytoprotection from oxidative injury (Elia et al., 1999). As only ferritin L chain was 
up-regulated in HCC, but not ferritin H chain, such evidence suggests that ferritin L 
chain alone may have particular functions in HCC, probably related to antioxidant 
function. 
Liver fatty acid binding protein (L-FABP) is an abundant protein in hepatocytes that 
binds most of the long chain fatty acids present in the cytosol. Some studies 
indicated that it is also a specific mediator of mitogenesis of rat hepatocytes (in 
it 
review, Sorof, 1994): (a) the synergy between the action of L-FABP and unsaturated 
r 
fatty acids, especially linoleic acid, in the promotion of cell proliferation; (b) the 
specific requirement for L-FABP in induction of mitogenesis by two classes of 
nongenotoxic hepatocarcinogenic peroxisome proliferators; and (c) the marked 
、 
elevations of L-FABP in rat liver during mitosis in normal and regenerating 
hepatocytes, and during the entire cell cycle in the hyperplastic and malignant 
hepatocytes that are produced by the genotoxic carcinogens. In addition, 
immunohistochemical staining also demonstrated that there was elevated expression 
in well-differentiated human HCC compared to the undifferentiated or immature 
ones (Suzuki et al., 1990). Thus its expression may be related to the progression of 
tumor cell malignancies and it is not surprising that it was found in the subtracted 
HCC cDNA library (blot A, clone D10). 
4.3.7 Summary 
Although the data that we reported here does not account for the amount of proteins 
expressed in the tissues under study, our findings can provide more information and 
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insights to the current understanding on the development of HCC especially the one 
induced by HBV. As a considerable number of candidate genes identified are 
consistent with the current knowledge on cancer development, we believed that the 
candidates in this pool of data are important and involved in hepatocarinogenesis or 
the altered metabolism in the tumor tissue. Further investigations on those candidates, 
especially those involved in signal transduction and gene transcription, may reveal 
other molecular events that occur during HCC development. The differential 
expression status of these candidates should be further studied in different stages of 
HCC tissues in order to have a clearer picture about their actions during tumor 
r 
progression. Such findings should help us to solve the unfinished puzzle about the 
underlying mechanisms of HBV-induced carcinogenesis. On the other hand, further 
studies on those candidates that are secretory proteins may be also helpful to the 
% 
exploration of novel HCC diagnostic markers for early detection of liver cancer. 
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The Coordinates of Dot Blots (in numerical order according to clone 
numbers) 
Clone no. Putative Identity 
Blot A- A01 1.1 kb m R N A upregulated in retinoic acid treated HL-60 neutrophilic cells 
Blot A- A03 3-hydroxy-3-methylglutaryl coenzyme A synthase (HMG-CoA) 
Blot A- A04 activating signal cointegrator 1 
Blot A- A05 acyI-CoA synthetase 4 (ACS4) 
Blot A- A06 acyl-CoA synthetase 4 (ACS4) 
Blot A- A07 adenosine deaminase, RNA-specif ic (ADAR) 
Blot A- A08 adipose differentiation-related protein (ADFP) 
Blot A- A09 ADP-ribosylation factor-like 1 (ARL1) 
Blot A- AlO aldehyde dehydrogenase (ALDH 1) 
| t 
Blot A- A11 aldehyde dehydrogenase, microsomal (ALD 10) 
Blot A- A12 aldehyde reductase 
B l o t A - B 0 1 aldo-keto reductase 
Blot A- B02 aldo-keto reductase 
Blot A- B03 aldo-keto reductase family 1，member B11 
Blot A- B04 angiopoietin-related protein 3 (ANGPTL3) 
Blot A- B05 annexin II (lipocortin II) (ANX2) 
B l o t A - B 0 6 apolipoprotein B-lOO (apoB) � 
Blot A- B07 apolipoprotein C-I (APOC 1) 
Blot A- B08 apolipoprotein H 
Blot A- B09 apolipoprotein M 
Blot A- B10 ATP cassette binding transporter 1 (ABC 1) 
B l o t A - B l l B-cell receptor associated protein (hBAP) mRNA, partial cds •* 
Blot A- B12 Bcl2, p53 binding protein Bbp/53BP2 (BBP/53BP2) 
Blot A- CO 1 beta-hexosaminidase beta chain 
Blot A- C02 cadherin 1, E-cadherin (epithelial) (CDH1) 
Blot A- C03 calcyclin 
Blot A- C04 calmodulin (CALM2) 
Blot A- C05 canalicular muItispecific organic anion transporter 
Blot A- C06 CD24 signal transducer 
Blot A- C07 ceruloplasmin 
Blot A- C08 colon carcinoma laminin-binding protein 
Blot A- C09 complement component 1 
Blot A- C10 complement factor B 
Blot A- C11 complement H factor 
Blot A - C 1 2 cyclin G 
Blot A- DO 1 dendritic cell protein (GA 17) 
Blot A- D02 dihydrodiol dehydrogenase 
Blot A- D03 dihydrodiol dehydrogenase 
Blot A- D04 translation elongation factor 1-alpha (EF1A) 
Blot A- D07 enolase 1, (alpha) ( E N 0 1 ) 
Blot A- D08 epoxide hydrolase 
Blot A- D09 E R G B transcription factor 
Blot A- D10 fatty acid binding protein, liver (L-FABP) 
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Blot A - D 1 1 ferritin H chain 
Blot A - D 1 2 ferritin H chain 
B l o t A - E 0 1 ferritin L chain 
Blot A- E02 fibrillarin (FBL) 
Blot A- E03 fibronectin (FN precursor) 
Blot A- E04 fibronectin (FN precursor) 
Blot A- E05 focal adhesion kinase (FAK) 
Blot A- E06 galectin 4 (lectin, galactoside-binding, soluble, 4) (LGALS4) 
Blot A- E07 galectin 4 (lectin, galactoside-binding, soluble, 4) (LGALS4) 
Blot A- E08 GDP dissociation inhibitor 2 (GDI2) 
Blot A- E09 78 kdalton glucose-regulated protein (GRP78) (BiP) 
Blot A- ElO glutamine synthetase in tumorous liver 
Blot A- E l l glyoxalase I ( G L 0 1 ) 
Blot A- E12 guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 (GNB2L1) 
Blot A- F01 H2A histone family, member Z (H2AFZ) 
Blot A- F02 H3 histone, family 3A (H3F3A) 
Blot A- F03 haptoglobin alpha 1S (Hpa 1S) “ 
Blot A- F04 heat shock lOkDprotein 1 (chaperonin 10) (HSPE1) 
Blot A- F05 heat shock 60kD protein 1 (chaperonin) (HSPD 1) 
Blot A- F06 heat shock 90kD protein 1, beta (HSPCB) 
Blot A- F07 heme-regulated initiation factor 2-aIpha kinase (HRI) 
Blot A- F08 heterogeneous nuclear ribonucleoprotein A2/B1 (HNRPA2B 1) 
Blot A- F09 heterogeneous nuclear ribonucleoprotein K (HNRPK) 
Blot A- F10 histidine-rich glycoprotein (HRG) � 
Blot A- F11 histone R N A hairpin-binding protein 
Blot A- F12 hXBP-1 transcription factor 
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A 
Blot A- GO 1 hydratase (triftinctional protein), beta subunit (HADHB) 
Blot A- G02 immature colon carcinoma transcript 1 (ICT1) -
Blot A- G03 IMP (inosine monophosphate) dehydrogenase 2 ( lMPDH2) 
Blot A- G04 inhibitor o f g r o w t h 1 (D^G1) 
Blot A- G08 insulin receptor 
Blot A- G09 integral membrane protein, calnexin, (IP90) 
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 
Blot A - G 1 0 (ITGB1) 
Blot A - G 1 1 IRLB 
Blot A- G12 isocitrate dehydrogenase 3 O^AD+) beta ( IDH3B) 
B lot A- HO 1 isopentenyl-diphosphate delta isomerase (IDI 1) 
Blot A- H02 kininogen 
Blot B- A01 L3 pigment (L3) 
Blot B- A02 La protein 
Blot B- A03 lactate dehydrogenase A (LDHA) 
Blot B- A04 laminin receptor 1 (67kD, ribosomal protein SA) (LAMR1) 
‘ Blot B- A05 leukocyte cell-derived chemotaxin 2 (LECT2) 
Blot B- A06 lipoamide dehydrogenase 
Blot B- A07 lysosomal acid lipase 
Blot B- A08 lysozyme (LYZ) 
Blot B- A09 malate dehydrogenase 1, N A D (soluble) (MDH 1) 
Blot B- AlO mannosidase II isozyme, alpha 
Blot B- A11 megakaryocyte stimulating factor (MSF) 
1 1 3 
Appendix A 
Blot B- A12 MEGF9 (high-molecular-weight proteins with multiple EGF-like motifs) 
B l o t B - B 0 1 Membrane cofactor protein 
Blot B- B02 microglobulin, beta-2- (B2M) 
Blot B- B03 microsomal triglyceride transfer protein large subunit (MTP) 
Blot B- B04 mitochondrial genome 
Blot B- B05 monoamine oxidase B (MAOB) 
Blot B- B06 M-phase phosphoprotein homolog 
Blot B- B07 multiple inositol polyphosphate phosphatase 
Blot B- B08 mutL homolog 1 (MLH 1) 
Blot B- B09 NAD(P)H menadione oxidoreductase 
Blot B- B10 NAD(P)H:quinone oxidoreductase 
Blot B- B l l NAD(P)H:quinone oxidoreductase2 0^QO2) 
Blot B - B 1 2 NADP dependent leukotriene b4 12-hydroxydehydrogenase, partial cds 
Blot B- C01 Nck-associated protein 1 O^apl) 
Blot B- C02 N-ethylmaleimide-sensitive factor (NSF) 
Blot B- C03 NS1 -binding protein O^S 1 -BP) 
It 
Blot B- C04 nucleophosmin-retinoic acid receptor alpha fusion protein NPM-RAR short form 
Blot B- C05 organic anion transport polypeptide 2 
Blot B- C06 osteopontin 
Blot B- C07 osteopontin 
Blot B- C08 outer membrane receptor Tom20 (TOM20) 
Blot B- C09 p l8prote in 
B l o t B - C 1 0 p66shc (SHC) 
Blot B- C11 PDZ domain containing 1 (PDZK1) mRNA, and translated products � 
Blot B- C I 2 peroxisomal 70 kD membrane protein 
Blot B- D01 peroxisomal farnesylated protein (PXF) 
Blot B- D02 phenylalanine hydroxylase (PAH) 
Blot B- D03 phosphate carrier protein, mitochondrial 
Blot B- D04 phosphatidylethanolamine binding protein, human homologue of rat 
Blot B- D05 phosphoglucomutase 1 (PGM1) 
Blot B- D06 phosphoribosyl pyrophosphate synthetase 2 (PRPS2) 
Blot B- D07 plasma protease (C1) inhibitor 
Blot B- D08 polyadenylate binding protein II 
Blot B- D09 polyubiquitin UbC 
B l o t B - D 1 0 prefoldin subunit 2 
Blot B- D11 procollagen-lysine，2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2 (PLOD2) 
Blot B - D 1 2 prostaglandin F synthase 
Blot B- EOl prostate cancer overexpressed gene 1 (P0V1) 
Blot B- E02 leuserpin 2’ protease inhibitor (hLS2) 
Blot B- E03 proteasome (prosome, macropain) subunit, alpha type, 3 
Blot B- E04 proteasome (prosome, macropain) subunit, alpha type, 5 (PSMA5) 
Blot B- E05 proteasome subunit X 
Blot B- E06 Protein inhibitor of activated STAT X (PlASX-BETA) 
‘ Blot B- E07 protein S (alpha) (PROS 1) 
Blot B- E08 protein tyrosine phosphatase type I.VA, member 1 (PTP4A1) 
Blot B- E09 putative tumor suppressor mRNA 
Blot B- ElO pyrroline-5-carboxylate synthase long form (P5CSL) 
Blot B- El 1 RAB13, member RAS oncogene family (RAB13) 
Blot B- E12 RET Fused Gene (RFG) 
Blot B- F01 retinol binding protein (RBP) 
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Blot B- F02 ribonuclease H1 (RNASEH 1) 
Blot B- F03 small nuclear ribonucleoprotein D1 polypeptide (16kD) (SNRPD 1) 
Blot B- F04 ribosomal protein L13 (RPL13) 
Blot B- F05 ribosomal protein L27 (RPL27) 
Blot B- F06 ribosomal protein L3 
Blot B- F07 ribosomal protein L31 (RPL31) 
Blot B- F08 ribosomal protein L31 (RPL31) 
Blot B- F09 ribosomal protein L32 (RPL32) 
Blot B- F10 ribosomal protein L39 (RPL39) 
Blot B- F11 ribosomal protein L5 pseudogene 
B l o t B - F 1 2 ribosomal protein L7 
Blot B- G01 ribosomal protein S l l (RPS11) 
Blot B- G02 ribosomal protein S13 (RPS13) 
Blot B- G03 ribosomal protein S15a (RPS 15A) 
Blot B- G04 ribosomal protein S25 (RPS25) 
Blot B- G05 ribosomal protein S27 
Blot B- G06 ribosomal protein S27a (RPS27A) “ 
Blot B- G07 ribosomal protein S4, X-linked (RPS4X) 
Blot B- G08 ribosomal protein S7 (RPS7) 
Blot B- G09 ribosomal RNA, 28S 
S100 calcium-binding protein A10(annexin II ligand, calpactin I，light polypeptide ( p l l ) ) 
B l o t B - G 1 0 (S100A10) 
Blot B- G11 SDK3, nuclear protein 
Blot B- G12 selenoprotein P, plasma, 1 (SEPP1) � 
Blot B- HO 1 serine/threonine kinase (BTAK) 
Blot B- H02 serum albumin (ALB) 
Blot C- AO 1 serum albumin (HSA) 
Blot C- A02 signal recognition particle 19kD (SRP 19) 
Blot C- A03 SPARC (osteonectin) (secreted protein, acidic, cysteine-rich) -
Blot C- A04 spectrin, beta, non-erythrocytic 1 (SPTBN 1) 
Blot C- A05 S-protein (vitronectin) 
Blot C- A06 staufen (Drosophila, RNA-binding protein) (STAU) 
Blot C- A07 Stearoyl-CoA desaturase (SCD) 
Blot C- A08 Stearoyl-CoA desaturase (SCD) 
B l o t C - A 0 9 superoxide dismutase, Cuy'Zn (S0D1) 
Blot C- AlO superoxide dismutase, manganese 
Blot C- A11 syntaxin binding protein 3 (STXBP3) 
Blot C- A12 TATA box binding protein (TBP)-associated factor, RNA polymerase II, G, 32kD (TAF2G) 
Blot C- B01 T-cell activation protein (PGR1) 
Blot C- B02 TCP 1 (t-complex-1) ring complex, polypeptide 5 (TRIC5) 
Blot C- B03 thioredoxin reductase 1 (TXNRD 1) 
Blot C- B04 thymosin b e t a 4 
Blot C- B05 thyroid autoantigen 70kD (Ku antigen) 
“ Blot C- B06 thyroid receptor interacting protein 15 (TRIP 15) 
Blot C- B07 TIAR, nucleolysin ‘ 
Blot C- B08 tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) (TFPI) 
Blot C- B09 tomoregulin 
Blot C- B10 transcription factor IID 
Blot C - B 1 1 transferrin (TF) 
Blot C - B 1 2 transferrin (TF) 
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Blot C- C01 transgelin 2 
Blot C- C02 transketolase (tk) 
Blot C- C03 translation elongation factor 1-alpha (EF1A) 
Blot C- C04 translation elongation factor 1 -alpha (EF1A) 
Blot C- C05 translation elongation factor-1 -gamma 
Blot C- C06 translation initiation factor 2B-epsilon 
Blot C- C07 translation initiation factor 3’ subunit 10 (lheta, 150/170kD) (EIF3S10) 
Blot C- C08 translation initiation factor 3，subunit 7 
Blot C- C09 translocase Timl7a, mitochondrial inner membrane preprotein 
Blot C- C10 translocon-associated protein gamma (signal sequence receptor, gamma) (SSR3) 
Blot C - C l l triosephosphate isomerase 1 (TP11) 
BlotC-C12 tRNA synthetase, asparaginyl- (NARS) 
Blot C- D01 tRNA synthetase, glycyl- (GARS) 
Blot C- D02 tropomyosin TM30, cytoskeletal 
Blot C- D03 tropomyosin, skeletal muscle alpha- (hTM-alpha) 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide 
It 
Blot C- D04 (YWHAZ) 
Blot C- D05 ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52) 
Blot C- D06 ubiquitin-conjugating enzyme UbcH2 
Blot C- D07 UDP-glucose 6-dehydrogenase 
Blot C- D08 UDP-glucuronosyltransferasc (UGT1) gene isozyme, exon 5 
Blot C- D09 UDP-glucuronosyItransferase, liver microsomal (UDPGT) 
Blot C- D10 voltage-dependent anion channel 1 (VDAC 1) 
Blot C- D11 voltage-dependent anion channel 3 � 
Blot C- D12 von Hippel-Lindau tumor suppressor (VHL) gene 
Blot C- E01 zinc finger protein 216 (ZNF216) 
Blot C- E02 novel gene 
Blot C- E03 novel (T2L300) 
Blot C- E04 novel (T2L303) ‘ 
BlotC- E05 novel (T2L379) 
Blot C- E06 novel (T2L305) 
BIot C- E07 novel (T2L471) 
Blot C- E08 novel (T2L350) 
Blot C- E09 novel (T2L288) 
Blot C - E 1 0 novel (T2L444) 
Blot C-E11 novel (T2L273) 
Blot C- E12 novel (T2L327) 
Blo tC-F01 novel (T2AF7) 
B lo tC-F02 novel (T2DA1) 
Blot C- F03 novel (T2L373) 
Blot C- F04 novel (T2BE2) 
Blot C- F05 novel (T2CD4) 
Blot C- F06 novel (T2L380) 
Blot C- F07 novel (T2DA5) 
Blot C- F08 novel (T2AH3) 
Blot C- F09 novel (T2CC3) 
BIot C -F10 novel (T2L329) 
Blot C-F11 novel (T2DE1) 
B lo tC-F12 novel (T2L342) 
B lo tC-G01 novel (T2L254) 
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Blot C- G02 novel (T2DC6) 
B lo tC-G03 novel (T2BA1) 
B lo tC-G04 novel (T2BF12) 
Blot C- G05 novel (T2FF8) 
Blot C- G06 novel (T2FE5) 
Blot C- G07 novel (T2HA3) 
Blot C- G08 novel (T2L428) 
Blot C- G09 novel (T2DA3) 
Blot C - G 1 0 novel (T2BA6) 
Blot C-G11 novel (T2FG2) 
Blot C - G 1 2 novel (T2L424) 
B lo tC-H01 novel (T2L116) 
Blot C- H02 novel (T2L075) 
Blot C- H03 novel (T2AF6) 
B lo tC-H04 novel (T2KF10) 
Blot C- H05 novel (T2GF9) 
B lo tC-H06 novel (T2DD1) “ 
Blot C- H07 novel (T2GE10), 
B lo tC-H08 novel (T2L168) 
Blot C- H09 novel (T2FC6) 
Blot C - H 1 0 novel (T2CD5) 
% 
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Appendix B 
The Coordinates of Dot Blots (in alphabetical order according to 
putative identity) 
Clone no. Putative Identity 
Blot A- A01 1.1 kb m R N A upregulated in retinoic acid treated HL-60 neutrophilic cells 
Blot A- A03 3-hydroxy-3-methylglutaryl coenzyme A synthase (HMG-CoA) 
Blot A- E09 78 kdalton glucose-regulated protein (GRP78) (BiP) 
Blot A- A04 activating signal cointegrator 1 
Blot A- A05 acyl-CoA synthetase 4 (ACS4) 
Blot A- A06 acyl-CoA synthetase 4 (ACS4) 
Blot A- A07 adenosine deaminase, RNA-specif ic (ADAR) 
Blot A- A08 adipose differentiation-related protein (ADFP) 
Blot A- A09 ADP-ribosylation factor-like 1 (ARL1) ,, 
Blot A- A10 aldehyde dehydrogenase (ALDH 1) 
Blot A - A I 1 aldehyde dehydrogenase, microsomal (ALD10) 
Blot A- A12 aldehyde reductase 
Blot A- B01 aldo-keto reductase 
Blot A- B02 aldo-keto reductase 
Blot A- B03 aldo-keto reductase family 1，member B11 
Blot A- B04 angiopoietin-related protein 3 (ANGPTL3) 
Blot A- B05 annexin II (lipocortin II) (ANX2) � 
Blot A- B06 apolipoprotein B-lOO (apoB) 
Blot A- B07 apolipoprotein C-I (APOC 1) 
Blot A- B08 apolipoprotein H 
Blot A- B09 apolipoprotein M 
Blot A- B10 ATP cassette binding transporter 1 (ABC1) "" 
Blot A- B l l B-cell receptor associated protein (hBAP) mRNA, partial cds 
Blot A- B12 Bcl2, p53 binding protein Bbp/53BP2 (BBP/53BP2) 
Blot A- CO 1 beta-hexosaminidase beta chain 
Blot A- C02 cadherin 1，E-cadherin (epithelial) (CDH 1) 
Blot A- C03 calcyclin 
Blot A- C04 calmodulin (CALM2) 
Blot A- C05 canalicular multispecific organic anion transporter 
Blot A- C06 CD24 signal transducer 
Blot A- C07 ceruloplasmin 
Blot A- C08 colon carcinoma laminin-binding protein 
Blot A- C09 complement component 1 
Blot A- C10 complement factor B 
Blot A- C11 complement H factor 
Blot A - C 1 2 cyclin G 
Blot A- D01 dendritic cell protein (GA17) . 
Blot A- D02 dihydrodiol dehydrogenase 
Blot A- D03 dihydrodiol dehydrogenase 
Blot A- D07 enolase 1, (alpha) ( E N 0 1 ) 
Blot A- D08 epoxide hydrolase 
Blot A- D09 E R G B transcription factor 
Blot A- D10 fatty acid binding protein, liver (L-FABP) 
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Blot A - D 1 1 ferritin H chain 
Blot A - D 1 2 ferritin H chain 
Blot A- E01 ferritin L chain 
Blot A- E02 fibrillarin (FBL) 
Blot A- E03 fibronectin (FN precursor) 
Blot A- E04 fibronectin (FN precursor) 
Blot A- E05 focal adhesion kinase (FAK) 
Blot A- E06 galectin 4 (lectin, galactoside-binding, soluble, 4) (LGALS4) 
Blot A- E07 galectin 4 (lectin, galactoside-binding, soluble, 4) (LGALS4) 
Blot A- E08 GDP dissociation inhibitor 2 (GD12) 
Blot A- ElO glutamine synthetase in tumorous liver 
Blot A- E11 glyoxalase I (GLO 1) 
Blot A- E12 guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 (GNB2L1) 
Blot A- F01 H2A histone family, member Z (H2AFZ) 
Blot A- F02 H3 histone, family 3A (H3F3A) 
Blot A- F03 haptoglobin alpha 1S (Hpa 1S) 
It 
Blot A- F04 heat shock 1 OkD protein 1 (chaperonin 10) (HSPE 1) 
Blot A- F05 heat shock 60kD,protein 1 (chaperonin) (HSPD 1) 
Blot A- F06 heat shock 90kD protein 1，beta (HSPCB) 
Blot A- F07 heme-regulated initiation factor 2-aIpha kinase (HRI) 
Blot A- F08 heterogeneous nuclear ribonucleoprotein A2/B1 (HNRPA2B 1) 
Blot A- F09 heterogeneous nuclear ribonucleoprotein K (HNRPK) 
Blot A- F10 histidine-rich glycoprotein (HRG) 
Blot A- F11 histone RNA hairpin-binding protein � 
Blot A- F12 hXBP-1 transcription factor 
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A 
Blot A- G01 hydratase (trifunctional protein), beta subunit (HADHB) 
Blot A- G02 immature colon carcinoma transcript 1 (1CT1) 
Blot A- G03 IMP (inosine monophosphate) dehydrogenase 2 ( lMPDH2) ‘ 
Blot A- G04 inhibitor of growth 1 (ING 1) 
Blot A- G08 insulin receptor 
Blot A- G09 integral membrane protein, calnexin, (IP90) 
integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 
Blot A - G 1 0 (ITGB1) 
Blot A - G 1 1 IRLB 
Blot A- G12 isocitrate dehydrogenase 3 C^AD+) beta (IDH3B) 
Blot A- HO 1 isopentenyl-diphosphate delta isomerase (IDI 1) 
Blot A- H02 kininogen 
B l o t B - A 0 1 L3 pigment (L3) 
Blot B- A02 La protein 
Blot B- A03 lactate dehydrogenase A (LDHA) 
Blot B- A04 laminin receptor 1 (67kD, ribosomal protein SA) (LAMR 1) 
Blot B- A05 leukocyte cell-derived chemotaxin 2 (LECT2) 
Blot B- E02 leuserpin 2’ protease inhibitor (hLS2) 
Blot B- A06 lipoamide dehydrogenase 
Blot B- A07 lysosomal acid lipase 
Blot B- A08 lysozyme (LYZ) 
Blot B- A09 malate dehydrogenase 1, N A D (soluble) (MDH 1) 
Blot B- AlO mannosidase II isozyme, alpha 
Blot B- A l 1 megakaryocyte stimulating factor (MSF) 
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Blot B- A12 MEGF9 (high-molecular-weight proteins with multiple EGF-like motifs) 
Blot B- B01 Membrane cofactor protein 
Blot B- B02 microglobulin, beta-2- (B2M) 
Blot B- B03 microsomal triglyceride transfer protein large subunit (MTP) 
Blot B- B04 mitochondrial genome 
Blot B- B05 monoamine oxidase B (MAOB) 
Blot B- B06 M-phase phosphoprotein homolog 
Blot B- B07 multiple inositol polyphosphate phosphatase 
Blot B- B08 mutL homolog 1 (MLH1) 
Blot B- B09 NAD(P)H menadione oxidoreductase 
Blot B-B10 NAD(P)H:quinone oxidoreductase 
Blot B- B11 NAD(P)H:quinone oxidoreductase2 0^QO2) 
Blot B- B12 NADP dependent leukotriene b4 12-hydroxydehydrogenase, partial cds 
Blot B- C01 Nck-associated protein 1 (Napl) 
Blot B- C02 N-ethylmaleimide-sensitive factor O^SF) 
Blot C- H03 novel (T2AF6) 
Blo tC-F01 novel (T2AF7) 
Blot C- F08 novel (T2AH3) , 
B lo tC-G03 novel (T2BA1) 
Blot C - G 1 0 novel (T2BA6) 
Blot C- F04 novel (T2BE2) 
Blot C- G04 novel (T2BF12) 
Blot C- F09 novel (T2CC3) 
Blot C- F05 novel (T2CD4) � 
Blot C - H 1 0 novel (T2CD5) 
Blot C- F02 novel (T2DA1) 
Blot C- G09 novel (T2DA3) 
Blot C- F07 novel (T2DA5) 
Blot C- G02 novel (T2DC6) ‘ 
B lo tC-H06 novel (T2DD1) 
Blot C-F11 novel (T2DE1) 
Blot C- H09 novel (T2FC6) 
Blot C- G06 novel (T2FE5) 
Blot C- G05 novel (T2FF8) 
Blot C-G11 novel (T2FG2) 
Blot C- H07 novel (T2GE10) 
Blot C- H05 novel (T2GF9) 
Blot C- G07 novel (T2HA3) 
B lo tC-H04 novel (T2KF10) 
Blot C- H02 novel (T2L075) 
Blot C- H01 novel (T2L116) 
B lo tC-H08 novel (T2L168) 
Blot C- GO 1 novel (T2L254) 
Blot C-E11 novel (T2L273) 
Blot C- E09 novel (T2L288) 
Blot C- E03 novel (T2L300) 
Blot C- E04 novel (T2L303) 
Blot C- E06 novel (T2L305) 
Blot C - E 1 2 novel (T2L327) 
Blot C - F 1 0 novel (T2L329) 
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Blot C - F 1 2 novel (T2L342) 
Blot C- E08 novel (T2L350) 
Blot C- F03 novel (T2L373) 
Blot C- E05 novel (T2L379) 
Blot C- F06 novel (T2L380) 
Blot C - G 1 2 novel (T2L424) 
Blot C- G08 novel (T2L428) 
Blot C - E 1 0 novel (T2L444) 
Blot C- E07 novel (T2L471) 
Blot C- E02 novel gene 
Blot B- C03 NS1 -binding protein O^S 1 -BP) 
Blot B- C04 nucleophosmin-retinoic acid receptor alpha fusion protein NPM-RAR short form 
Blot B- C05 organic anion transport polypeptide 2 
Blot B- C06 osteopontin 
Blot B- C07 osteopontin 
Blot B- C08 outer membrane receptor Tom20 (TOM20) ,. 
B l o t B - C 0 9 p l8prote in 
B l o t B - C 1 0 p66shc ( S H C ) , 
Blot B - C 1 1 PDZ domain containing 1 (PDZK1) mRNA, and translated products 
Blot B - C 1 2 peroxisomal 70 kD membrane protein 
Blot B- DO 1 peroxisomal farnesylated protein (PXF) 
Blot B- D02 phenylalanine hydroxylase (PAH) 
Blot B- D03 phosphate carrier protein, mitochondrial 
Blot B- D04 phosphatidylethanolamine binding protein, human homologue of rat � 
Blot B- D05 phosphoglucomutase 1 (PGM 1) 
Blot B- D06 phosphoribosyl pyrophosphate synthetase 2 (PRPS2) 
Blot B- D07 plasma protease (C 1) inhibitor 
Blot B- D08 polyadenylate binding protein II 
Blot B- D09 polyubiquitin UbC “ 
Blot B- D10 prefoldin subunit 2 
Blot B- D11 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2 (PLOD2) 
B l o t B - D 1 2 prostaglandin F synthase 
Blot B- EOl prostate cancer overexpressed gene 1 (P0V1) 
Blot B- E03 proteasome (prosome, macropain) subunit, alpha type, 3 
Blot B- E04 proteasome (prosome, macropain) subunit, alpha type, 5 (PSMA5) 
Blot B- E05 proteasome subunit X 
Blot B- E06 Protein inhibitor of activated STAT X (PIASX-BETA) 
Blot B- E07 protein S (alpha) (PROS 1) 
Blot B- E08 protein tyrosine phosphatase type IVA, member 1 (PTP4A 1) 
Blot B- E09 putative tumor suppressor mRNA 
Blot B- ElO pyrroline-5-carboxylate synthase long form (P5CSL) 
Blot B- El 1 RAB13, member RAS oncogene family (RAB13) 
Blot B- E12 RET Fused Gene (RFG) 
Blot B- F01 retinol binding protein (RBP) 
Blot B- F02 ribonuclease H1 (RNASEH 1) 
Blot B- F04 ribosomal protein L13 (RPL13) 
Blot B- F05 ribosomal protein L27 (RPL27) 
Blot B- F06 ribosomal protein L3 
Blot B- F07 ribosomal protein L31 (RPL31) 
Blot B- F08 ribosomal protein L31 (RPL31) 
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Blot B- F09 ribosomal protein L32 (RPL32) 
Blot B- F10 ribosomal protein L39 (RPL39) 
Blot B- F11 ribosomal protein L5 pseudogene 
Blot B- F12 ribosomal protein L7 
Blot B- G01 ribosomal protein S11 (RPS11) 
Blot B- G02 ribosomal protein S13 (RPS 13) 
Blot B- G03 ribosomal protein S15a (RPS15A) 
Blot B- G04 ribosomal protein S25 (RPS25) 
Blot B- G05 ribosomal protein S27 
Blot B- G06 ribosomal protein S27a (RPS27A) 
Blot B- G07 ribosomal protein S4, X-linked (RPS4X) 
Blot B- G08 ribosomal protein S7 (RPS7) 
Blot B- G09 ribosomal RNA, 28S 
S100 calcium-binding protein AlO (annexin 11 ligand, calpactin I’ light polypeptide ( p l l ) ) 
B l o t B - G 1 0 (S100A10) 
B l o t B - G l l SDK3, nuclear protein 
| t 
Blot B- G12 selenoprotein P, plasma, 1 (SEPP1) 
Blot B- HO 1 serine/threonine.kinase (BTAK) 
Blot B- H02 serum albumin (ALB) 
Blot C- AO 1 serum albumin (HSA) 
Blot C- A02 signal recognition particle 19kD (SRP 19) 
Blot B- F03 small nuclear ribonucleoprotein D1 polypeptide (16kD) (SNRPD 1) 
Blot C- A03 SPARC (osteonectin) (secreted protein, acidic, cysteine-rich) 
Blot C- A04 spectrin, beta, non-erythrocytic 1 (SPTBN1) � 
Blot C- A05 S-protein (vitronectin) 
Blot C- A06 staufen (Drosophila, RNA-binding protein) (STAU) 
Blot C- A07 Stearoyl-CoA desaturase (SCD) 
Blot C- A08 Stearoyl-CoA desaturase (SCD) 
B l o t C - A 0 9 superoxide dismutase, Cu/Zn ( S 0 D 1 ) “ 
Blot C- AlO superoxide dismutase, manganese 
Blot C- A11 syntaxin binding protein 3 (STXBP3) 
Blot C- A12 TATA box binding protein (TBP)-associated factor, RNA polymerase II, G, 32kD (TAF2G) 
Blot C- BO 1 T-cell activation protein (PGR 1) 
Blot C - B02 TCP1 (t-compIex-1) ring complex, polypeptide 5 (TRIC5) 
Blot C- B03 thioredoxin reductase 1 (TXNRD1) 
Blot C- B04 thymosin b e t a 4 
Blot C- B05 thyroid autoantigen 70kD (Ku antigen) 
Blot C- B06 thyroid receptor interacting protein 15 (TRIP 15) 
Blot C- B07 TIAR, nucleolysin 
Blot C- B08 tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) (TFPI) 
Blot C- B09 tomoregulin 
Blot C- B10 transcription factor IID 
Blot C - B 1 1 transferrin (TF) 
Blot C- B12 transferrin (TF) 
Blot C- C01 transgelin 2 
Blot C - C02 transketolase (tk) 
Blot A- D04 translation elongation factor 1-alpha (EF1A) 
Blot C- C03 translation elongation factor 1-alpha (EF1A) 
Blot C- C04 translation elongation factor 1 -alpha (EF1A) 
Blot C- C05 translation elongation factor-1 -gamma 
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Blot C- C06 translation initiation factor 2B-epsilon 
Blot C- C07 translation initiation factor 3，subunit 10 (theta, 150/170kD) (EIF3S10) 
Blot C- C08 translation initiation factor 3，subunit 7 
Blot C- C09 translocase Timl7a , mitochondrial inner membrane preprotein 
Blot C- C10 translocon-associated protein gamma (signal sequence receptor, gamma) (SSR3) 
Blot C- C11 triosephosphate isomerase 1 (TPI 1) 
B l o t C - C 1 2 tRNAsynthetase, asparaginyl-(NARS) 
Blot C- DO 1 tRNA synthetase, glycyl- (GARS) 
Blot C- D02 tropomyosin TM30，cytoskeletal 
Blot C- D03 tropomyosin, skeletal muscle alpha- (hTM-alpha) 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide 
Blot C- D04 (YWHAZ) 
Blot C- D05 ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52) 
Blot C- D06 ubiquitin-conjugating enzyme UbcH2 
Blot C- D07 UDP-glucose 6-dehydrogenase 
Blot C- D08 UDP-glucuronosyltransferase (UGT1) gene isozyme, exon 5 
i> 
Blol C- D09 UDP-glucuronosyltransferase, liver microsomal (UDPGT) 
Blot C- D10 voltage-dependent anion channel 1 (VDAC 1) 
Blot C- D11 voltage-dependent anion channel 3 
Blot C- D12 von Hippel-Lindau tumor suppressor (VHL) gene 
Blot C- EOl zinc finger protein 216 (ZNF216) 
、 
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